[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 132
1. Bortolin MT, Zanussi S, Talamini R, Simonelli C, Pratesi C, Tedeschi R, Abbruzzese L, Manuele R, Rupolo M, Tirelli U, De Paoli P: Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT). AIDS Res Hum Retroviruses; 2010 Feb;26(2):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).
  • The kinetics and predictive value of HIV-1 DNA (HIV DNA) levels in relapsed or refractory HIV lymphoma patients, treated with high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT), were investigated.
  • HIV DNA was measured by real-time PCR in the peripheral blood mononuclear cells (PBMCs) of 22 patients observed for a median follow-up of 31.0 months.
  • At baseline, HIV DNA was found to be correlated with HIV-1 RNA (HIV RNA) (r = 0.56), but not with CD4(+) counts (r = -0.10).
  • HIV RNA load was under control for the entire follow-up, while HIV DNA levels were almost always detectable (baseline levels vs. 1 year from ASCT levels, p > 0.05).
  • Baseline HIV DNA levels were significantly different between alive and deceased patients (p = 0.03), and the overall survival (OS) analysis showed that for patients with higher HIV DNA levels at baseline there was a higher and nearly significant risk of death if compared to patients with lower levels (HR, 8.33, 95% CI, 0.99-70.06, p = 0.05).
  • Our study demonstrated that high HIV DNA levels at baseline could predict overall survival after ASCT in one of the largest cohorts of HIV lymphoma patients treated with salvage therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA, Viral / blood. HIV-1 / isolation & purification. Lymphoma, AIDS-Related / mortality. Stem Cell Transplantation. Viral Load


2. Ho SF, Fink C, Murray PI: Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma. Ocul Immunol Inflamm; 2005 Dec;13(6):471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.
  • We report an HIV-positive patient who developed a unilateral retinitis and subsequent intracranial lesions.
  • The finding of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS non-Hodgkin's lymphoma, which was subsequently confirmed on brain biopsy.
  • [MeSH-major] DNA, Viral / genetics. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321894.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


3. Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC: Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr; 2010 May 1;54(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.
  • HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.
  • Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.
  • Genetic abnormalities are known to play a significant role in HIV(-) lymphomagenesis.
  • Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.
  • These data demonstrate the ability to molecularly classify B-ARL lymphomas by gene expression and identified DNA copy number alterations targeted in B-ARL.
  • [MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216076.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Gotoh M, Kitahara T, Iguchi T, Izumi M, Mukai K, Ohyashiki K: [HIV-related multiple non-Hodgkin lymphomas]. Rinsho Ketsueki; 2008 Nov;49(11):1552-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-related multiple non-Hodgkin lymphomas].
  • He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).
  • We diagnosed double lymphomas related to AIDS.
  • The patient received anti-retroviral therapy, and started the CHOP regimen for the double lymphomas, resulting in transient improvement.
  • Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.
  • This case suggested that cancer generation was promoted by low immunity, although it is known that ambivalent tumors such as non-Hodgkin lymphomas can occur frequently.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047787.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


5. Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R: Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect; 2008 Jun;10(7):748-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) causes EBV-associated lymphoproliferative diseases in patients with profound immune suppression.
  • Most of these diseases are life-threatening and the prognosis of AIDS-associated lymphomas is extremely unfavorable.
  • We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-associated lymphoproliferative diseases.
  • These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-associated lymphoproliferative diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538617.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin
  •  go-up   go-down


6. Epeldegui M, Widney DP, Martínez-Maza O: Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol; 2006 Sep;18(5):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions.
  • PURPOSE OF REVIEW: We discuss recently published studies that elucidate the pathogenesis of AIDS-associated lymphoma.
  • RECENT FINDINGS: Several recent reports have provided valuable new information on the role of gamma-herpesviruses in the pathogenesis of AIDS-associated lymphoma.
  • In addition to this, significant new information has become available on how B cell activation-associated DNA-modifying events, involving activation-induced cytidine deaminase and DNA polymerase-eta, contribute to the molecular lesions that result in AIDS-associated lymphoma.
  • In particular, new evidence that oncogenic viruses can directly induce activation-induced cytidine deaminase expression and oncogene mutation in human B cells is of central relevance to better understanding the pathogenesis of AIDS-associated lymphoma.
  • SUMMARY: New information provides insights into the contributions of immune dysfunction and oncogenic virus infection to pathogenesis of AIDS-associated lymphoma, and may lead to new potential targets for therapeutic intervention in these cancers.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / virology. Lymphoma, B-Cell / genetics. Oncogenic Viruses / pathogenicity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894291.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI35040; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA70080; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein; EC 3.5.4.5 / Cytidine Deaminase
  • [Number-of-references] 28
  •  go-up   go-down


7. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
  • It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin's lymphoma treatment response, but a poor outcome has been reported in patients with positive P-gp expression.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin's lymphoma HIV-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.
  • In patients having achieved complete remission, the median disease-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF: Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med; 2005 Jan;6(1):21-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
  • BACKGROUND: Neurological disorders are common in HIV-infected patients.
  • Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.
  • OBJECTIVES: To investigate the clinical utility of flow cytometry immunophenotyping (FCI) in diagnosing or discarding leptomeningeal involvement in HIV-infected patients and to compare its sensitivity with that of conventional cytological methods.
  • METHODS: Fifty-six cerebrospinal fluid (CSF) samples from 29 HIV-infected patients were independently evaluated by flow cytometry and cytology.
  • RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.
  • This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670248.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Carbone A, Gloghini A, Vaccher E, Marchetti G, Gaidano G, Tirelli U: KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. J Clin Pathol; 2005 Oct;58(10):1039-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype.
  • BACKGROUND: Kaposi sarcoma associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) associated lymphomas, which often develop in human immunodeficiency virus (HIV) infected patients with advanced AIDS, present predominantly as primary effusion lymphoma (PEL) or, less frequently, as "solid" extracavitary based lymphomas, associated with serous effusions.
  • These last lymphomas, also called "solid PEL", have been reported before the development of an effusion lymphoma and after resolution of PEL.
  • Interestingly, KSHV/HHV-8 associated lymphomas that present as solid or extracavitary based lesions in HIV seropositive patients without serous effusions have been reported recently.
  • METHODS/RESULTS: This paper provides evidence for the existence of a previously undescribed KSHV/HHV-8 associated lymphoma in HIV seronegative patients without serous effusions.
  • These lymphomas exhibit a predilection for the lymph nodes and display anaplastic large cell morphology.
  • B and T cell associated antigens and other commonly used lymphoid markers were absent or weakly demonstrable in a fraction of the tumour cells.
  • CONCLUSIONS: Analysis of viral infection and immunohistological studies are of primary importance to define this lymph node based KSHV/HHV-8 associated lymphoma with anaplastic large cell morphology and plasmablastic immunophenotype occurring in HIV seronegative patients without serous effusions.
  • [MeSH-major] Herpesviridae Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma, Large B-Cell, Diffuse / virology
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. HIV Seronegativity. Humans. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] Leuk Lymphoma. 1999 Oct;35(3-4):379-87 [10706463.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):753-5 [10782162.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] AIDS Patient Care STDS. 2002 Apr;16(4):139-45 [12015867.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):630 [12827623.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] J Clin Virol. 2003 Oct;28(2):155-64 [12957185.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):693-7 [15105661.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312 [9620643.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1637-42 [9881964.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):992-4 [10435572.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Hum Pathol. 2002 Aug;33(8):846-9 [12203218.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1363-7 [12360052.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):831-44 [12525917.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):418-22 [7517959.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):318-23 [8759892.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Ann Intern Med. 1996 Nov 15;125(10):822-5 [8928989.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1198-201 [9129085.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):303-4 [9335459.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • (PMID = 16189148.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ PMC1770735
  •  go-up   go-down


10. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature.
  • The gastrointestinal (GI) tract is a common internal organ to be involved by human immunodeficiency virus (HIV)-related malignancies.
  • It is the second most common site for Kaposi sarcoma after skin, and the commonest visceral site, for Kaposi sarcoma in AIDS patients.
  • GI lymphomas have been documented in approximately 25% of AIDS patients with systemic lymphomas.
  • Moreover, GI involvement of AIDS-lymphoma has been associated with poor prognosis and short survival.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • As a result of active antiretroviral therapy, patients infected with HIV are living longer and are consequently at increased risk for development of cancer.
  • Therefore, it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors may change in the future.
  • In this paper, the clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Gastrointestinal Neoplasms / pathology. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / pathology. Sarcoma, Kaposi / pathology


11. Epeldegui M, Vendrame E, Martínez-Maza O: HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res; 2010 Dec;48(1-3):72-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.
  • HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL).
  • The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation.
  • In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.
  • [MeSH-major] AIDS-Related Opportunistic Infections / immunology. Acquired Immunodeficiency Syndrome / immunology. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / immunology. HIV / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology


12. Kelemen K, Cao W, Peterson LC, Evens AM, Variakojis D: Primary mediastinal large B-cell lymphoma in HIV: report of two cases. J Hematop; 2009 Mar;2(1):45-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma in HIV: report of two cases.
  • Primary mediastinal large B cell lymphoma (PMLBCL) is a subtype of diffuse large B cell lymphoma arising in the mediastinum with distinctive clinical and morphological features.
  • Though diffuse large B cell lymphoma is one of the most common non-Hodgkin lymphoma associated with AIDS, there are no data available regarding the association of HIV and PMLBCL.
  • We report here two cases of PMLBCL arising in AIDS patients.
  • One of the two patients, a 25-year-old woman who had localized disease and evidence of Epstein-Barr virus in lymphoma cells, did not respond to chemotherapy and died of disease progression 5 months after diagnosis.
  • The second patient, a 38-year-old male with disseminated disease, responded to therapy and is disease-free after 9 months of follow-up.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):44-54 [8465656.001]
  • [Cites] J Pathol. 1992 Aug;167(4):381-4 [1328576.001]
  • [Cites] Blood. 1991 Aug 1;78(3):780-8 [1713514.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Blood. 2007 Aug 1;110(3):972-8 [17400912.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Am J Med Sci. 2005 Mar;329(3):136-8 [15767818.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):1135-48 [8880201.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 19669223.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2713493
  •  go-up   go-down


13. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignancy and human immunodeficiency virus disease.
  • Certain skin cancers occur with increased frequency or altered course in patients infected with HIV.
  • Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.
  • The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.
  • Cutaneous T-cell lymphoma (CTCL) is rare in this population.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV.
  • [MeSH-major] HIV Infections / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


14. Vaghefi P, Martin A, Prévot S, Charlotte F, Camilleri-Broët S, Barli E, Davi F, Gabarre J, Raphael M, Poirel HA: Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status. AIDS; 2006 Nov 28;20(18):2285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.
  • BACKGROUND: The pathologic heterogeneity of AIDS related lymphomas (ARL) reflects several pathogenic mechanisms: chronic antigenic stimulation, Epstein-Barr virus (EBV) infection, and genomic abnormalities.
  • Genetic abnormalities, known to play a major role in lymphomas of non-immunocompromised patients, are not well characterized in ARL.
  • DNA-CNC tended to be more frequent in EBV-positive lymphomas with latency type II/III than in EBV-positive latency I or EBV-negative lymphomas.
  • Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.
  • The results suggested an inverse relationship between EBV infection (latency II/III), associated with deep acquired immune suppression, and the number of chromosomal alterations which may be explained by a direct role of viral proteins in lymphomagenesis by activation of signalling pathways without needing several genomic alterations.
  • [MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117014.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


15. Corti M, de Dios Soler M, Bare P, Villafañe MF, De Tezanos Pinto M, Perez Bianco R, Narbaitz M: [AIDS related lymphomas: Histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8]. Medicina (B Aires); 2010;70(2):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS related lymphomas: Histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8].
  • [Transliterated title] Linfomas asociados con la infección por el virus de la inmunodeficiencia humana: subtipos histológicos y asociación con los virus de Epstein Barr y Herpes-8.
  • Non-Hodgkin lymphomas (NHL) of the B-cell type are the second most common neoplasm among patients with human immunodeficiency virus (HIV) infection and AIDS.
  • Here, we evaluated 48 cases of AIDS-related lymphomas (ARL) diagnosed at the Histopathological Division of the Instituto de Investigaciones Hematológicas of the National Academy of Medicine.
  • Additionally, biotinilated oligonucleotides were used to determine the presence of DNA of the Human Herpes virus type-8 (HHV-8) in 14/14 biopsy smears corresponding to plasmablastic lymphomas (PL).
  • All were fenotype B cell lymphomas with an aggressive course and advanced neoplasm disease at the time of diagnosis.
  • Virological findings showed the strong association between EBV and AIDS-related NHL.
  • According to the histopathological subtype, the EBV genome was detected in 16/21 (76%) diffuse large B cell lymphomas, 1/3 Burkitt lymphoma and 3/4 (75%) of primary central nervous system lymphomas.
  • Hodgkin lymphoma were more frequent in males 18/20 (90%), with an aggressive clinical course and a significant predominance of the subtypes associated with worse prognosis (90% of cases).
  • We consider that all cases of AIDS related lymphomas should be assessed for the presence of EBV because its presence may play a role in the prognosis.
  • [MeSH-major] DNA, Viral / analysis. Herpesvirus 4, Human / genetics. Hodgkin Disease / virology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447898.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


16. Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA: Targeted therapies in multiple myeloma. Target Oncol; 2009 Jan;4(1):23-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increasing knowledge of the biology of multiple myeloma led the way for the development of novel drugs that have changed the management of the disease.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3269-76 [15249589.001]
  • [Cites] Blood. 2004 May 1;103(9):3271-7 [14726402.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5781-9 [16740717.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1520-9 [12393535.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2762-9 [12433678.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2641-9 [17525289.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1098-104 [17494860.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1329-37 [17906076.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):314-22 [15057291.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2187-95 [15512806.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1885-92 [9607928.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):5103-9 [15067094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19478-83 [17164332.001]
  • [Cites] Blood. 2006 May 15;107(10):4053-62 [16418332.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Nov;17(11):1717-34 [18922108.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):950-68 [17546631.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1857-61 [17546599.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):961-5 [17047643.001]
  • [Cites] Br J Haematol. 2007 Oct;139(1):55-63 [17854307.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:495-528 [15822187.001]
  • [Cites] Ann Rheum Dis. 1999 Nov;58 Suppl 1:I107-13 [10577986.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4251-8 [15930364.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] J Org Chem. 2005 Aug 5;70(16):6196-203 [16050677.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):674-80 [11477577.001]
  • [Cites] Handb Exp Pharmacol. 2006;(172):331-58 [16610366.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5640-5 [9865713.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5898-906 [15994968.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4653-65 [14581334.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11712-20 [16357183.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1166-72 [12402158.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):316-25 [16574547.001]
  • [Cites] Angew Chem Int Ed Engl. 2003 Jan 20;42(3):355-7 [12548698.001]
  • [Cites] Apoptosis. 2003 Aug;8(4):337-43 [12815276.001]
  • [Cites] Leukemia. 2004 May;18(5):962-6 [15029211.001]
  • [Cites] J Infect Dis. 2003 Mar 15;187(6):946-55 [12660941.001]
  • [Cites] Br J Haematol. 2007 Mar;136(6):814-28 [17341267.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4525-30 [12036884.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6469-78 [17975159.001]
  • [Cites] FEBS Lett. 2007 Jul 31;581(19):3652-7 [17475256.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1549-60 [17460700.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):797-816 [18070720.001]
  • [Cites] Br J Haematol. 2003 May;121(4):592-6 [12752100.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):937-45 [16355211.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1383-95 [15471951.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):602-6 [11740817.001]
  • [Cites] IUBMB Life. 2008 Jun;60(6):390-7 [18425793.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):865-74 [18245550.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612 [18070708.001]
  • [Cites] Blood. 2007 Jan 15;109(2):711-9 [17003375.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1369-78 [16923571.001]
  • [Cites] Cell Immunol. 2004 Aug;230(2):81-8 [15598423.001]
  • [Cites] Leuk Res. 1996 Jun;20(6):507-15 [8709623.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4181-7 [15304393.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Jun;5(6):635-47 [15242253.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):221-30 [15050914.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1787-90 [14512311.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6345-50 [16155018.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2615-22 [12816865.001]
  • [Cites] Blood. 2001 Jul 1;98(1):210-6 [11418482.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;194:63-72 [7534674.001]
  • [Cites] Blood. 2004 May 1;103(9):3521-8 [14715624.001]
  • [Cites] Blood. 2003 May 15;101(10):4055-62 [12531799.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1419-27 [11830495.001]
  • [Cites] Br J Haematol. 2004 Mar;124(5):595-603 [14871245.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3281-90 [17591945.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1169-79 [10480630.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):156-61 [15059137.001]
  • [Cites] Blood. 2006 Jan 15;107(2):655-60 [16046527.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6826-35 [17121904.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14 (9):2775-84 [18451245.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4213-8 [8797594.001]
  • [Cites] Mol Cancer Ther. 2008 Jun;7(6):1494-505 [18566220.001]
  • [Cites] Blood. 2004 Aug 1;104(3):607-18 [15090448.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1654-64 [18006697.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):385-7 [18297514.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):380-6 [10384139.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):621-9 [17255285.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Dec;21(6):1007-34, vii-viii [17996586.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8 [16344099.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4907-16 [16507771.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Mar;16(3):381-92 [17302532.001]
  • [Cites] Blood. 1995 Feb 15;85(4):863-72 [7849308.001]
  • [Cites] Best Pract Res Clin Haematol. 2005;18(4):509-24 [16026734.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S33-43 [17259557.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2846-52 [15087402.001]
  • [Cites] Invest New Drugs. 2006 Nov;24(6):529-35 [16791411.001]
  • [Cites] Leuk Res. 2006 Jul;30(7):849-58 [16494942.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4257-66 [16518413.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4322-9 [16118318.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5334-46 [15939924.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):407-19 [16286248.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 May;61(6):923-32 [17624530.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6383-91 [17616698.001]
  • [Cites] Curr Top Med Chem. 2006;6(11):1205-14 [16842157.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):502-7 [18297527.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1656-63 [17510321.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1604-12 [18480838.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2597-603 [7522634.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):88-95 [14734456.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3138-47 [15070696.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2305-13 [16489035.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1092-100 [16234364.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4188-93 [15319277.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2374-80 [17016430.001]
  • [Cites] Anticancer Drugs. 2003 Oct;14(9):669-82 [14551500.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2210-6 [12114422.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3111-6 [10955791.001]
  • [Cites] J Hematother Stem Cell Res. 2003 Feb;12(1):11-22 [12662432.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Leuk Lymphoma. 2008 Apr;49(4):677-89 [18398734.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5 [14695887.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s [17875788.001]
  • (PMID = 19343299.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Interleukin-6; 0 / NF-kappa B; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 67763-96-6 / Insulin-Like Growth Factor I
  • [Number-of-references] 136
  •  go-up   go-down


17. Osorio S G, Montenegro U C: [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review]. Rev Chilena Infectol; 2007 Apr;24(2):117-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review].
  • [Transliterated title] Linfomas asociados a infección por virus de inmunodeficiencia humana en un complejo hospitalario de la Región Metropolitana, Chile: 1990-2002. Reporte de 14 casos y revisión.
  • The association of HIV infection and lymphoma in patients attending at the South Health Metropolitan Reference Centre is presented.
  • RESULTS: 14 cases were detected, 10 non Hodgkin lymphoma patients (7 with high malignancy and 50% in stages III-IVB) and 4 with Hodgkin lymphoma (3 with mixed cellularity, 2 in stage IVB).
  • Ten patients were classified under stage C3 of AIDS CDC criteria, the mean CD4 count was 139 cells/mm3 and mean CV was 5,32 log.
  • Eighty six percent of patients presented with unique or multiples lymphonodes, with predominance of advanced lymphoma stage.
  • Conventional CHOP chemotherapy was the treatment for high risk and extended non Hodgkin lymphomas and for extended Hodgkin lymphomas the ABVD protocol was administered.
  • Global mortality in this series was 71%, attributable to tumor disease per se or to sepsis.
  • Four patients survived (18 to 50 months) in complete remission, 2 non Hodgkin lymphomas and 2 Hodgkin lymphomas.
  • The low incidence of lymphoma and AIDS association and the high frequency of lymphomas with localized or generalized lymphonodes in this series are remarkable.
  • [MeSH-major] Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Chile / epidemiology. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453069.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 30
  •  go-up   go-down


18. Benicchi T, Ghidini C, Re A, Cattaneo C, Casari S, Caimi L, Rossi G, Imberti L: T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation; 2005 Sep 15;80(5):673-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma.
  • BACKGROUND: One of the major concern for high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) for HIV-associated lymphoma is that posttransplant immunosuppression might worsen immune defects of HIV individuals.
  • Since the introduction of highly active antiretroviral therapy has made HSCT possible also in these patients, we analyzed whether the immune system already compromised by HIV infection might support an efficient T-cell recovery after HSCT.
  • METHODS: The kinetics and the extent of T-cell reconstitution were investigated before and after HSCT in four patients with HIV-related lymphoma (one with Hodgkin's Disease and three with non-Hodgkin's lymphoma) by measuring the thymic output, the level of IL-7 and the heterogeneity of T-cell repertoire.
  • CONCLUSIONS: High-dose therapy and HSCT in HIV patients under highly active antiretroviral therapy does not worsen the immune defects.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / therapy


19. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups: Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol; 2008 Feb;140(4):411-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
  • Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma.
  • This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with HIV-related DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact.
  • Complete response was achieved in 55 (69%) patients, with an estimated 3-year disease-free survival of 77% and 3-year overall survival of 56%.
  • In HIV-related DLBCL R-CHOP is feasible, safe and effective.
  • The prognosis depends on lymphoma-related parameters and on the response to HAART.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162120.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA: RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med; 2010 Jun 16;2(36):36ra43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.
  • AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells.
  • As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34(+)) hematopoietic progenitor cells expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme).
  • In vitro estimates of successful expression of the anti-HIV moieties were initially as high as 22% but declined to approximately 1% over 4 weeks of culture.
  • Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no unexpected infusion-related toxicities.
  • These results support the development of an RNA-based cell therapy platform for HIV.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Mol Ther. 2007 Jun;15(6):1182-8 [17406343.001]
  • [Cites] Hum Gene Ther. 2008 Jun;19(6):622-34 [18533892.001]
  • [Cites] J Gene Med. 2008 Oct;10(10):1059-70 [18642399.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Science. 2009 Mar 6;323(5919):1304-7 [19265012.001]
  • [Cites] Mol Ther. 2009 May;17(5):844-50 [19259065.001]
  • [Cites] Science. 2009 Nov 6;326(5954):818-23 [19892975.001]
  • [Cites] Gene Ther. 2010 Mar;17(3):389-99 [19865182.001]
  • [Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]
  • [Cites] Mol Ther. 2002 Apr;5(4):479-84 [11945076.001]
  • [Cites] Gene Ther. 2002 Aug;9(16):1055-64 [12140733.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1730-4 [12457288.001]
  • [Cites] Mol Ther. 2003 Mar;7(3):325-33 [12668128.001]
  • [Cites] Mol Ther. 2003 Jul;8(1):62-71 [12842429.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] Blood. 2004 Feb 1;103(3):796-803 [12920024.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] J Gene Med. 2004 Mar;6(3):268-77 [15026988.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):395-6 [3166513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9870-4 [1409715.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Jul 15;84(2):421-32 [7517715.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4618-28 [8639830.001]
  • [Cites] Gene Ther. 1996 Aug;3(8):717-24 [8854097.001]
  • [Cites] J Virol. 1997 Jun;71(6):4707-16 [9151864.001]
  • [Cites] J Virol. 1999 May;73(5):3649-60 [10196257.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Clin Immunol. 2005 Apr;115(1):26-32 [15870017.001]
  • [Cites] Mol Ther. 2005 Jul;12(1):77-86 [15963923.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):697-706 [16039909.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):900-9 [16115802.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):366-73 [16325473.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1751-60 [16269617.001]
  • [Cites] Clin Infect Dis. 2006 Apr 1;42(7):1003-10 [16511767.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3305-12 [16857988.001]
  • [Cites] Mol Ther. 2007 May;15(5):1024-33 [17356541.001]
  • [Cites] Methods Mol Biol. 2008;434:99-112 [18470641.001]
  • (PMID = 20555022.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043-49; United States / NIAID NIH HHS / AI / AI61839; United States / NHLBI NIH HHS / HL / R01 HL074704; United States / NIAID NIH HHS / AI / AI42552; United States / NCI NIH HHS / CA / CA107399-05; United States / NIAID NIH HHS / AI / P01 AI061839-04; United States / NIAID NIH HHS / AI / R37 AI029329; United States / NCRR NIH HHS / RR / RR000043-49; United States / NIAID NIH HHS / AI / AI061839-04; United States / NHLBI NIH HHS / HL / HL07470; United States / NCI NIH HHS / CA / P50 CA107399-05; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCRR NIH HHS / RR / RR025083-01; United States / NCI NIH HHS / CA / P30 CA33572-26; United States / NCRR NIH HHS / RR / S10 RR025083-01; United States / NIAID NIH HHS / AI / AI042552-11; United States / NCI NIH HHS / CA / P30 CA033572-29; United States / NCRR NIH HHS / RR / M01 RR000043; United States / NHLBI NIH HHS / HL / R01 HL074704-07; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NCI NIH HHS / CA / P30 CA033572; United States / NIAID NIH HHS / AI / R01 AI042552; United States / NCRR NIH HHS / RR / S10 RR025083; United States / NIAID NIH HHS / AI / R01 AI042552-11; United States / NCRR NIH HHS / RR / S10RR025083-01; United States / NHLBI NIH HHS / HL / HL074704-07; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA
  • [Other-IDs] NLM/ NIHMS305014; NLM/ PMC3130552
  •  go-up   go-down


21. Singh J, Malani AK, Ganguly S, Kambhampati S: HAART- and AIDS-related lymphomas. Blood; 2006 Nov 15;108(10):3621; author reply 3621-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HAART- and AIDS-related lymphomas.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • (PMID = 17085718.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


22. Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, De Paoli A, Dal Maso L, Franceschi S, Rezza G: Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study. J Acquir Immune Defic Syndr; 2009 Sep 1;52(1):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study.
  • OBJECTIVES: To provide survival estimates of Italian people with AIDS (PWA) in the highly active antiretroviral therapy era and to identify prognostic factors at diagnosis and illnesses present at death.
  • Non-Hodgkin lymphoma at AIDS diagnosis was the strongest negative prognostic factor, particularly in the first 12 months after AIDS (hazard ratio = 9.2, for primary brain lymphoma).
  • At death, non-AIDS-defining illnesses increased from 38.4% in 1999 to 56.9% in 2006, with non-AIDS-defining cancers rising from 3.7% to 8.7%.
  • CONCLUSIONS: Our study documented the prolonged survival of Italian PWA, the strong impact of non-Hodgkin lymphoma on mortality, and the increasing frequency of non-AIDS-defining illnesses at death.
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / mortality. Female. Humans. Italy / epidemiology. Longitudinal Studies. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / mortality. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448558.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. D'Souza GA, Sunad R, Rajagopalan N, Ananthamurthy A, Murthy KR, Babu K: NK/T-cell lymphoma in AIDS. J Assoc Physicians India; 2006 Nov;54:890-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T-cell lymphoma in AIDS.
  • A 42-year-old man diagnosed to be HIV positive and on highly active antiretroviral treatment (HAART), presented with double vision and gradual drooping of the left eyelid.
  • Further workup showed the mass to be an NK/T cell lymphoma.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Nose Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249261.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


24. Salemi M, Lamers SL, Huysentruyt LC, Galligan D, Gray RR, Morris A, McGrath MS: Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma. PLoS One; 2009 Dec 03;4(12):e8153
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma.
  • Despite highly active antiretroviral therapy (HAART), AIDS related lymphoma (ARL) occurs at a significantly higher rate in patients infected with the Human Immunodeficiency Virus (HIV) than in the general population.
  • HIV-infected macrophages are a known viral reservoir and have been shown to have lymphomagenic potential in SCID mice; therefore, there is an interest in determining if a viral component to lymphomagenesis also exists.
  • We sequenced HIV-1 envelope gp120 clones obtained post mortem from several tumor and non-tumor tissues of two patients who died with AIDS-related Non-Hodgkin's lymphoma (ARL-NH).
  • 1) high-resolution phylogenetic analysis showed a significant degree of compartmentalization between lymphoma and non-lymphoma viral sub-populations while viral sub-populations from lymph nodes appeared to be intermixed within sequences from tumor and non-tumor tissues, 2) a 100-fold increase in the effective HIV population size in tumor versus non-tumor tissues was associated with the emergence of lymphadenopathy and aggressive metastatic ARL, and 3) HIV gene flow among lymph nodes, normal and metastatic tissues was non-random.
  • The different population dynamics between the viruses found in tumors versus the non-tumor associated viruses suggest that there is a significant relationship between HIV evolution and lymphoma pathogenesis.
  • Moreover, the study indicates that HIV could be used as an effective marker to study the origin and dissemination of lymphomas in vivo.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Genetics. 2006 Apr;172(4):2665-81 [16489234.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):272-9 [17324334.001]
  • [Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]
  • [Cites] PLoS One. 2007;2(9):e950 [17895991.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Retrovirology. 2007;4:87 [18053211.001]
  • [Cites] BMC Evol Biol. 2007;7:214 [17996036.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):285-93 [19308068.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] Genetics. 2000 Jul;155(3):1429-37 [10880500.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]
  • [Cites] Mol Biol Evol. 2001 Jun;18(6):1001-13 [11371589.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] Science. 2004 Jan 16;303(5656):327-32 [14726583.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Mol Biol Evol. 2005 May;22(5):1185-92 [15703244.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • (PMID = 19997510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA096230-06; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA009126; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA09126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2780293
  •  go-up   go-down


25. Kang KM, Song DS, Park JM, Jung CK, Hong YS, Kang MW, Park CW: Four cases of non-Hodgkin's lymphoma in AIDS patients. Korean J Intern Med; 2006 Dec;21(4):266-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of non-Hodgkin's lymphoma in AIDS patients.
  • The incidence of opportunistic infection has decreased since the introduction of highly active antiretroviral therapy, so lymphoma is now far and away the most lethal complication of acquired immunodeficiency syndrome.
  • We have experienced four cases of NHL in AIDS patients.
  • The first patient was a 37 year old male who presented with left sided hemiplegia due to CNS lymphoma.
  • The second patient was a 40 year old male who was admitted because of jaundice; he was diagnosed as having lymphoma that exclusively involved the liver.
  • The third patient was a 38-year-old male who presented with palpable mass in the left cervical region, which was diagnosed as lymphoma.
  • Above three cases were confirmed as diffuse large B cell lymphoma.
  • The latter case is the first report of NHL involving the chest wall musculature in a Korean AIDS patient.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):863-73 [11298581.001]
  • [Cites] Korean J Intern Med. 2001 Mar;16(1):1-7 [11417298.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):349-51 [12688356.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2 [6265753.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] JAMA. 1989 Feb 3;261(5):719-24 [2536124.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • (PMID = 17249512.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891035
  •  go-up   go-down


26. Trobridge GD, Wu RA, Beard BC, Chiu SY, Muñoz NM, von Laer D, Rossi JJ, Kiem HP: Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One; 2009 Nov 02;4(11):e7693
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.
  • BACKGROUND: There is currently no effective AIDS vaccine, emphasizing the importance of developing alternative therapies.
  • Recently, a patient was successfully transplanted with allogeneic, naturally resistant CCR5-negative (CCR5Delta32) cells, setting the stage for transplantation of naturally resistant, or genetically modified stem cells as a viable therapy for AIDS.
  • Hematopoietic stem cell (HSC) gene therapy using vectors that express various anti-HIV transgenes has also been attempted in clinical trials, but inefficient gene transfer in these studies has severely limited the potential of this approach.
  • Here we evaluated HSC gene transfer of an anti-HIV vector in the pigtailed macaque (Macaca nemestrina) model, which closely models human transplantation.
  • METHODS AND FINDINGS: We used lentiviral vectors that inhibited both HIV-1 and simian immunodeficiency virus (SIV)/HIV-1 (SHIV) chimera virus infection, and also expressed a P140K mutant methylguanine methyltransferase (MGMT) transgene to select gene-modified cells by adding chemotherapy drugs.
  • The high marking levels allowed us to demonstrate protection from SHIV in lymphocytes derived from gene-modified macaque long-term repopulating cells that expressed an HIV-1 fusion inhibitor.
  • We observed a statistically significant 4-fold increase of gene-modified cells after challenge of lymphocytes from one macaque that received stem cells transduced with an anti-HIV vector (p<0.02, Student's t-test), but not in lymphocytes from a macaque that received a control vector.
  • We also established a competitive repopulation assay in a second macaque for preclinical testing of promising anti-HIV vectors.
  • The vectors we used were HIV-based and thus efficiently transduce human cells, and the transgenes we used target HIV-1 genes that are also in SHIV, so our findings can be rapidly translated to the clinic.
  • CONCLUSIONS: Here we demonstrate the ability to select protected HSC-derived lymphocytes in vivo in a clinically relevant nonhuman primate model of HIV/SHIV infection.
  • This approach can now be evaluated in human clinical trials in AIDS lymphoma patients.
  • In this patient setting, chemotherapy would not only kill malignant cells, but would also increase the number of MGMTP140K-expressing HIV-resistant cells.
  • This approach should allow for high levels of HIV-protected cells in AIDS patients to evaluate AIDS gene therapy.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Jul 10;288(2):222-35 [12095387.001]
  • [Cites] Gene Ther. 2010 Jan;17(1):37-49 [19741733.001]
  • [Cites] J Med Primatol. 2002 Aug;31(4-5):237-56 [12390546.001]
  • [Cites] Science. 2003 Jun 13;300(5626):1749-51 [12805549.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2036-9 [12829768.001]
  • [Cites] Nat Rev Drug Discov. 2003 Aug;2(8):624-34 [12904812.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] J Clin Invest. 2003 Nov;112(10):1581-8 [14617759.001]
  • [Cites] J Virol. 2004 Jan;78(2):568-75 [14694088.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] Curr Gene Ther. 2004 Mar;4(1):15-31 [15032611.001]
  • [Cites] Blood. 2004 May 15;103(10):3710-6 [14739227.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4062-9 [14976042.001]
  • [Cites] J Immunol. 1985 Feb;134(2):971-6 [3871222.001]
  • [Cites] Immunogenetics. 1985;21(3):235-46 [3872841.001]
  • [Cites] Hum Gene Ther. 1999 Nov 20;10(17):2769-78 [10584923.001]
  • [Cites] Microbes Infect. 2000 Feb;2(2):223-9 [10742694.001]
  • [Cites] AIDS. 1999;13 Suppl A:S113-20 [10885770.001]
  • [Cites] Hum Gene Ther. 2000 Sep 20;11(14):2025-37 [11020801.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:318-29 [11131719.001]
  • [Cites] J Pharmacol Exp Ther. 2001 May;297(2):524-30 [11303039.001]
  • [Cites] Hum Gene Ther. 2001 Jun 10;12(9):1013-9 [11399224.001]
  • [Cites] Mol Ther. 2002 Jan;5(1):33-41 [11786043.001]
  • [Cites] J Virol. 1992 Apr;66(4):2232-9 [1548759.001]
  • [Cites] J Virol. 1992 Dec;66(12):7517-21 [1433527.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6221-7 [7954470.001]
  • [Cites] J Med Primatol. 1996 Jun;25(3):163-74 [8892037.001]
  • [Cites] J Virol. 1997 May;71(5):3932-9 [9094670.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1936-45 [9581836.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Curr Opin Biotechnol. 1998 Oct;9(5):457-63 [9821272.001]
  • [Cites] Science. 1999 Jan 29;283(5402):682-6 [9924027.001]
  • [Cites] Blood. 2005 Feb 1;105(3):997-1002 [15494421.001]
  • [Cites] Methods Mol Biol. 2005;309:261-72 [15990406.001]
  • [Cites] Hum Gene Ther. 2005 Dec;16(12):1355-66 [16390267.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Nat Biotechnol. 2006 Jun;24(6):687-96 [16732270.001]
  • [Cites] Hum Gene Ther. 2006 Jun;17(6):577-88 [16776567.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Retrovirology. 2006;3:76 [17078891.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):76-85 [17164778.001]
  • [Cites] Blood. 2007 Jan 1;109(1):65-70 [16968897.001]
  • [Cites] J Virol. 2007 Mar;81(6):2700-12 [17182671.001]
  • [Cites] PLoS Pathog. 2007 Apr;3(4):e54 [17432934.001]
  • [Cites] Hum Gene Ther. 2007 May;18(5):451-6 [17536975.001]
  • [Cites] Exp Hematol. 2007 Jul;35(7):1132-9 [17588482.001]
  • [Cites] J Virol. 2007 Nov;81(22):12210-7 [17804491.001]
  • [Cites] Nat Med. 2007 Dec;13(12):1389-90 [18064013.001]
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5537-43 [18388180.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Hum Gene Ther. 2009 Apr;20(4):325-36 [19267665.001]
  • [Cites] Cell. 2002 Aug 23;110(4):521-9 [12202041.001]
  • (PMID = 19888329.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK047754; United States / NIAID NIH HHS / AI / R21 AI063959; United States / NIAID NIH HHS / AI / AI063959; United States / NIAID NIH HHS / AI / AI061839; United States / NHLBI NIH HHS / HL / P01 HL053750; United States / NIDDK NIH HHS / DK / DK056465; United States / NIDDK NIH HHS / DK / DK047754; United States / NIDDK NIH HHS / DK / P30 DK056465; United States / NIAID NIH HHS / AI / R01 AI080326; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NHLBI NIH HHS / HL / HL053750
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines
  • [Other-IDs] NLM/ PMC2765621
  •  go-up   go-down


27. Madan RA, Chang VT, Dever LL: An uncommon presentation of HIV-related lymphoma. AIDS Patient Care STDS; 2007 Jul;21(7):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon presentation of HIV-related lymphoma.
  • Although highly active antiretroviral therapy has improved the clinical course of patients with HIV, this population remains at a significantly increased risk for non-Hodgkin's lymphoma (NHL).
  • We encountered a patient with HIV-related NHL who presented with a thoracic spinal cord compression and had a complicated clinical course as a result of the atypical presentation.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / virology. Spinal Cord Compression / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651024.001).
  • [ISSN] 1087-2914
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Levine AM: Management of AIDS-related lymphoma. Curr Opin Oncol; 2008 Sep;20(5):522-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related lymphoma.
  • PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.
  • Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.
  • RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients.
  • The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.
  • The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.
  • High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.
  • Addition of rituximab is associated with improved response rates, without an increase in infections.
  • Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.
  • Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106654.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


29. Marotta D, Sgambato A, Cerciello S, Magarelli N, Martini M, Larocca LM, Maccauro G: Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. World J Surg Oncol; 2008;6:111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature.
  • BACKGROUND: The risk of developing lymphoma is greatly increased in HIV infection.
  • Musculoskeletal manifestations of the human immunodeficiency virus (HIV) are common and are sometimes the initial presentation of the disease.
  • HIV-related neoplastic processes that affect the musculoskeletal system include Kaposi's sarcoma and non-Hodgkin's lymphoma, the latter being mainly localized at lower extremities, spine and skull.
  • In March 2004 she was diagnosed HIV positive and contemporary got pregnant.
  • A final diagnosis of diffuse large B-cell lymphoma was made.
  • HIV infection is still under control.
  • CONCLUSION: In this report, we present a case of diffuse large B-cell lymphoma localized in the soft tissue of the shoulder in a HIV infected patient.
  • Authors want to underline this case for the rare position, the big size and the association with HIV infection.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Pregnancy Complications, Neoplastic / pathology. Pregnancy Outcome. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Immunohistochemistry. Pregnancy. Risk Assessment. Shoulder. Surgical Procedures, Operative / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S82-5 [12734486.001]
  • [Cites] Radiology. 1980 Feb;134(2):521-3 [7352243.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):359-66 [3578646.001]
  • [Cites] Br J Radiol. 1989 Jan;62(733):81 [2914198.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):455-9 [7790558.001]
  • [Cites] Bol Asoc Med P R. 1995 Oct-Dec;87(10-12):158-61 [8924158.001]
  • [Cites] Crit Rev Diagn Imaging. 1996 Sep;37(4):305-47 [8894398.001]
  • [Cites] Clin Radiol. 1997 Mar;52(3):203-12 [9091255.001]
  • [Cites] Radiol Clin North Am. 1997 Sep;35(5):1167-89 [9298091.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1998 Feb;27(2):128-34 [9506198.001]
  • [Cites] Semin Ultrasound CT MR. 1998 Apr;19(2):200-8 [9567324.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):88-96 [9888708.001]
  • [Cites] Clin Orthop Relat Res. 1999 Mar;(360):221-30 [10101328.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):329-32 [16321866.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1443-5 [17515361.001]
  • [Cites] J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):312-20 [12374482.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2002 Sep;88(5):518-21 [12399719.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2405-7 [12613532.001]
  • [Cites] Skeletal Radiol. 2004 Jun;33(6):311-20 [15127244.001]
  • (PMID = 18939988.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


30. Mani D, Dorer RK, Aboulafia DM: Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma; 2009 Aug;9(4):316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
  • In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non- AIDS-defining cancers (NADCs).
  • As patients survive longer, long-term therapy-related complications take on greater importance.
  • Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
  • With the diagnosis of therapy-related acute myeloid leukemia (AML) secured, he began induction chemotherapy with idarubicin and cytarabine.
  • Through a literature search, we were able to identify 4 additional cases of therapy-related AML in AIDS patients following chemotherapy for lymphomas.
  • The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).
  • With many HIV-infected patients surviving alkylator and topoisomerase inhibitor-based treatment and radiation therapy for AIDS-defining cancers and NADCs, long-term follow-up for therapy-related complications assumes greater importance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717383.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


31. Goldstein MA, Naidich TP, Silverman ME: Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS.
  • Accurately distinguishing between cerebral toxoplasmosis and primary central nervous system lymphoma (PCNSL), still the most common secondary CNS mass lesion complications of AIDS, has long represented a diagnostic challenge in those with HIV.
  • A young adult male with AIDS presented with evolving ophthalmoplegias, Parinaud's syndrome and gait dysfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):554-5 [12695179.001]
  • [Cites] Neurology. 1998 Jan;50(1):21-6 [9443452.001]
  • (PMID = 21686485.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027744
  •  go-up   go-down


32. Dunleavy K, Wilson WH, Kaplan LD: The case for rituximab in AIDS-related lymphoma. Blood; 2006 Apr 1;107(7):3014-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case for rituximab in AIDS-related lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Lymphoma, Non-Hodgkin / drug therapy. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • (PMID = 16554492.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


33. Voisset C, Weiss RA, Griffiths DJ: Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev; 2008 Mar;72(1):157-96, table of contents
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease.
  • Four human retroviruses are currently known, including human immunodeficiency virus type 1, which causes AIDS, and human T-lymphotropic virus type 1, which causes cancer and inflammatory disease.
  • Here, we aim to bring together the data on "novel" retroviral infections in humans by critically examining the evidence for those putative viruses that have been linked with disease and the likelihood that they represent genuine human infections.
  • In addition, some of the difficulties associated with obtaining formal proof of causation for common or ubiquitous agents such as HERVs are discussed.
  • [MeSH-minor] Chronic Disease. Humans. Virology / methods

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Cancer. 2014 Mar;24(3):382 [24557431.001]
  • [Cites] N Engl J Med. 1994 Jan 20;330(3):172-7 [8264739.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Aug 10;18(12):861-6 [12201909.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Dec 29;355(1404):1831-41 [11205344.001]
  • [Cites] Ann Neurol. 2001 Oct;50(4):434-42 [11601494.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):789-801 [16909114.001]
  • [Cites] Amyotroph Lateral Scler. 2007 Apr;8(2):67-72 [17453631.001]
  • [Cites] J Virol. 2004 Oct;78(19):10310-9 [15367597.001]
  • [Cites] Ann Neurol. 2004 Jul;56(1):10-9 [15236397.001]
  • [Cites] Infect Immun. 1978 Apr;20(1):69-72 [78897.001]
  • [Cites] Clin Microbiol Rev. 2001 Jan;14(1):165-76 [11148008.001]
  • [Cites] J Virol. 1982 Jul;43(1):191-200 [6286997.001]
  • [Cites] Arch Virol. 1983;77(2-4):239-47 [6314937.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6047-55 [15208658.001]
  • [Cites] Trends Immunol. 2002 Feb;23(2):57-8 [11929125.001]
  • [Cites] J Autoimmun. 1990 Apr;3(2):137-66 [2160242.001]
  • [Cites] Acta Neurol Scand Suppl. 1997;169:49-58 [9174640.001]
  • [Cites] Retrovirology. 2005;2:19 [15766379.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14572-9 [15310846.001]
  • [Cites] Virus Genes. 2003 May;26(3):291-315 [12876457.001]
  • [Cites] J Virol Methods. 1998 Aug;73(2):151-61 [9766886.001]
  • [Cites] Virology. 1995 Jun 1;209(2):374-83 [7778272.001]
  • [Cites] Nature. 1986 Jul 10-16;322(6075):177-8 [3014352.001]
  • [Cites] Viral Immunol. 1997;10(3):137-47 [9344336.001]
  • [Cites] Med Microbiol Immunol. 1975;161(2):133-44 [806773.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Jun 29;356(1410):867-76 [11405934.001]
  • [Cites] Arthritis Rheum. 1997 Nov;40(11):2016-21 [9365091.001]
  • [Cites] Neurology. 1991 Jan;41(1):31-4 [1985291.001]
  • [Cites] Lancet. 1989 May 20;1(8647):1096-100 [2566049.001]
  • [Cites] Nature. 2000 Jul 6;406(6791):15-6 [10894520.001]
  • [Cites] J Infect Dis. 1978 Apr;137(4):421-7 [206631.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):177-80 [15202831.001]
  • [Cites] Cell. 1998 Oct 2;95(1):14-6; discussion 16 [9778243.001]
  • [Cites] Mult Scler. 2006 Dec;12(6):698-703 [17262996.001]
  • [Cites] Virology. 1995 Feb 20;207(1):292-6 [7871741.001]
  • [Cites] Nature. 1989 Sep 7;341(6237):72-4 [2788824.001]
  • [Cites] Trends Genet. 2007 Jul;23(7):326-33 [17524519.001]
  • [Cites] J Mol Evol. 2004 Nov;59(5):642-56 [15693620.001]
  • [Cites] J Virol. 2001 Feb;75(4):1783-9 [11160676.001]
  • [Cites] Trends Microbiol. 1998 Apr;6(4):160-5 [9587194.001]
  • [Cites] J Gen Virol. 2001 Oct;82(Pt 10):2515-8 [11562544.001]
  • [Cites] J Virol. 1986 Nov;60(2):589-98 [3021993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):961-6 [9023365.001]
  • [Cites] Immunol Rev. 1993 Feb;131:79-92 [8387458.001]
  • [Cites] Ann Neurol. 1996 Nov;40(5):805-9 [8957025.001]
  • [Cites] Science. 1988 Jun 10;240(4858):1427-35 [3287617.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):627-38 [9125244.001]
  • [Cites] Lancet. 1998 Jan 3;351(9095):33 [9433428.001]
  • [Cites] Br J Dermatol. 2004 Oct;151(4):737-45 [15491412.001]
  • [Cites] Acta Neurol Scand. 2000 Apr;101(4):229-38 [10770518.001]
  • [Cites] Arthritis Rheum. 1994 Mar;37(3):349-58 [8129790.001]
  • [Cites] Genomics. 2001 Mar 15;72(3):314-20 [11401447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13013-8 [14557543.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):957-64 [12459734.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Feb;11(2):231-7 [7537972.001]
  • [Cites] Nat Neurosci. 2004 Oct;7(10):1088-95 [15452578.001]
  • [Cites] Eur J Cancer. 1974 Jul;10(7):419-24 [4141964.001]
  • [Cites] J Virol. 2000 Apr;74(7):3321-9 [10708449.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7223-30 [16103073.001]
  • [Cites] Proc Am Thorac Soc. 2005;2(2):132-40 [16113481.001]
  • [Cites] Ann Neurol. 2000 Jun;47(6):707-17 [10852536.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6977-81 [2457923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7831-5 [1380169.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):847-9 [11237007.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8960-5 [17875739.001]
  • [Cites] Virology. 2005 Jun 20;337(1):1-6 [15914215.001]
  • [Cites] J Clin Invest. 1989 Apr;83(4):1430-5 [2467924.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):81-90 [17013901.001]
  • [Cites] Am J Pathol. 1984 Jan;114(1):46-55 [6362424.001]
  • [Cites] Arch Virol. 1980;64(2):155-66 [7387404.001]
  • [Cites] J Hum Genet. 1999;44(5):343-7 [10496080.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 Dec;8(12):1981-9 [1337258.001]
  • [Cites] Exp Hematol. 2004 Jun;32(6):520-5 [15183892.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):446-51 [10646903.001]
  • [Cites] Adv Cancer Res. 1988;51:183-276 [3146900.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5173-9 [7585568.001]
  • [Cites] Immunol Lett. 1996 Nov;53(2-3):101-4 [9024985.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):826-9 [8752279.001]
  • [Cites] Bioessays. 1999 Feb;21(2):164-74 [10193189.001]
  • [Cites] J Med Virol. 2000 Aug;61(4):527-32 [10897073.001]
  • [Cites] Cancer Res. 1958 Jun;18(5):491-509 [13547041.001]
  • [Cites] Cell. 1996 May 3;85(3):291-7 [8616883.001]
  • [Cites] Nature. 1985 Nov 28-Dec 4;318(6044):390 [3877876.001]
  • [Cites] J Gen Virol. 1993 Jan;74 ( Pt 1):65-72 [7678635.001]
  • [Cites] Bioinformatics. 2000 Feb;16(2):79-95 [10842727.001]
  • [Cites] J Virol Methods. 2003 Jul;111(1):1-11 [12821191.001]
  • [Cites] J Neurol. 1990 Oct;237(6):352-5 [2277268.001]
  • [Cites] J Virol. 2005 Sep;79(17):10890-901 [16103141.001]
  • [Cites] Virology. 1996 Aug 15;222(2):451-6 [8806530.001]
  • [Cites] J Virol. 1991 Apr;65(4):1870-6 [2002547.001]
  • [Cites] Biol Psychiatry. 2002 Jun 15;51(12):979-87 [12062882.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3697-700 [52874.001]
  • [Cites] J Virol. 2005 Jul;79(13):8230-6 [15956568.001]
  • [Cites] Virology. 1989 Nov;173(1):214-22 [2815583.001]
  • [Cites] J Virol. 2000 Apr;74(8):3715-30 [10729147.001]
  • [Cites] J Exp Med. 1911 Apr 1;13(4):397-411 [19867421.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S261-7 [8797733.001]
  • [Cites] Transfusion. 2002 Jul;42(7):886-91 [12375661.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4894-9 [15044706.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4480-4 [8506289.001]
  • [Cites] Clin Exp Immunol. 1992 Jul;89(1):46-51 [1628425.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1617-21 [6154936.001]
  • [Cites] Mult Scler. 1995 Jun;1(2):78-81 [9345456.001]
  • [Cites] Rheumatology (Oxford). 2000 Sep;39(9):950-4 [10986298.001]
  • [Cites] Am J Med. 1998 Jan;104(1):99-100 [9528725.001]
  • [Cites] J Immunol. 1986 Dec 1;137(11):3440-3 [3023483.001]
  • [Cites] J Virol. 2005 Jan;79(1):341-52 [15596828.001]
  • [Cites] Ann Epidemiol. 1990 Oct;1(1):71-92 [1669491.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Nov;20(11):1223-9 [15588344.001]
  • [Cites] J Natl Cancer Inst. 1973 Apr;50(4):1081-4 [4703773.001]
  • [Cites] Eur Respir J. 2000 Aug;16(2):330-2 [10968511.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):921-4 [9637142.001]
  • [Cites] Lancet. 1998 May 30;351(9116):1620-4 [9620716.001]
  • [Cites] J Virol. 2006 Aug;80(16):8030-7 [16873259.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 Nov 1;12(16):1509-17 [8911576.001]
  • [Cites] Lancet Infect Dis. 2002 Mar;2(3):156-62 [11944185.001]
  • [Cites] Arch Virol. 1993;129(1-4):357-61 [8385922.001]
  • [Cites] Cell. 1993 Aug 13;74(3):529-40 [8394220.001]
  • [Cites] J Virol. 2005 Oct;79(19):12507-14 [16160178.001]
  • [Cites] Virology. 2007 May 25;362(1):120-30 [17258784.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8492-6 [2479024.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1127-9 [1701273.001]
  • [Cites] Genomics. 2003 Mar;81(3):329-35 [12659816.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 Jul 1;12(10):931-40 [8798978.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Apr;11(4):527-9 [7632467.001]
  • [Cites] Semin Arthritis Rheum. 1995 Oct;25(2):117-33 [8578312.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Mar;3(3):172-80 [17334340.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Clin Microbiol Rev. 2006 Jan;19(1):80-94 [16418524.001]
  • [Cites] J Neuroimmunol. 2005 Mar;160(1-2):195-203 [15710473.001]
  • [Cites] Genome Res. 1999 Jun;9(6):525-40 [10400920.001]
  • [Cites] AIDS Res Hum Retroviruses. 1990 Dec;6(12):1361-2 [2078414.001]
  • [Cites] Acta Neurol Scand. 1991 Dec;84(6):507-13 [1724334.001]
  • [Cites] J Natl Cancer Inst. 1972 Apr;48(4):1095-9 [4336873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4634-9 [11296294.001]
  • [Cites] J Virol. 1999 Jun;73(6):4662-9 [10233925.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4449-54 [11296288.001]
  • [Cites] Br J Exp Pathol. 1958 Oct;39(5):519-28 [13584702.001]
  • [Cites] Nature. 1986 Jul 10-16;322(6075):176-7 [3014351.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3178-84 [16920956.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Lancet. 1978 Oct 7;2(8093):796 [80725.001]
  • [Cites] Nat Genet. 1999 Mar;21(3):257-8 [10080172.001]
  • [Cites] J Gen Virol. 1978 Jul;40(1):175-81 [357681.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):1-3 [10623645.001]
  • [Cites] J Biol Chem. 2001 Jan 19;276(3):1896-903 [11054415.001]
  • [Cites] J Virol. 2004 Mar;78(6):2780-9 [14990698.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12891-6 [16118271.001]
  • [Cites] Hum Mutat. 2007 Feb;28(2):137-42 [17152059.001]
  • [Cites] Immunol Rev. 1999 Apr;168:287-303 [10399081.001]
  • [Cites] J Gen Virol. 1978 Dec;41(3):587-97 [217951.001]
  • [Cites] J Virol. 1998 Jul;72(7):5955-66 [9621058.001]
  • [Cites] J Virol. 2004 Jul;78(14):7852-60 [15220463.001]
  • [Cites] Clin Exp Immunol. 2002 Apr;128(1):75-82 [11982593.001]
  • [Cites] Virology. 2002 Apr 25;296(1):1-5 [12036312.001]
  • [Cites] Lancet. 1997 Sep 20;350(9081):875-9 [9310614.001]
  • [Cites] Nature. 1985 Nov 14-20;318(6042):154-60 [2997627.001]
  • [Cites] Genomics. 2005 Mar;85(3):330-7 [15718100.001]
  • [Cites] J Invest Dermatol. 1999 Oct;113(4):587-94 [10504445.001]
  • [Cites] J Exp Med. 1986 Jan 1;163(1):87-100 [3079815.001]
  • [Cites] Ann Neurol. 1990 Oct;28(4):574-7 [2252368.001]
  • [Cites] J Autoimmun. 2001 Jun;16(4):457-62 [11437494.001]
  • [Cites] Am J Pathol. 1995 Jun;146(6):1433-43 [7778682.001]
  • [Cites] Nat Med. 1997 Mar;3(3):282-6 [9055854.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7636-44 [16751411.001]
  • [Cites] J Med Virol. 1993 Mar;39(3):229-32 [8468566.001]
  • [Cites] Cancer. 1993 May 15;71(10):2971-6 [8387872.001]
  • [Cites] Res Virol. 1997 May-Jun;148(3):191-206 [9201810.001]
  • [Cites] Mol Cell. 2004 Dec 22;16(6):849-59 [15610729.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5510-6 [12359761.001]
  • [Cites] Retrovirology. 2004;1:32 [15476554.001]
  • [Cites] PLoS Pathog. 2007 May 4;3(5):e64 [17480120.001]
  • [Cites] J Virol. 1997 Jun;71(6):4581-8 [9151852.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4172-80 [15899808.001]
  • [Cites] Rev Med Virol. 2004 May-Jun;14(3):169-77 [15124233.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6261-5 [17384150.001]
  • [Cites] Nature. 2000 Sep 21;407(6802):286 [11014164.001]
  • [Cites] J Natl Cancer Inst. 1971 Feb;46(2):299-307 [4329955.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6651-9 [16061645.001]
  • [Cites] Lancet. 2004 Mar 20;363(9413):932-7 [15043960.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):904-7 [15829964.001]
  • [Cites] J Gen Virol. 1997 Jun;78 ( Pt 6):1389-98 [9191935.001]
  • [Cites] Biotechniques. 1996 Apr;20(4):608-12 [8800679.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):1025-9 [12792764.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5234-41 [6091872.001]
  • [Cites] J Invest Dermatol. 2004 Aug;123(2):407-9 [15245444.001]
  • [Cites] Nat New Biol. 1973 Aug 1;244(135):146 [4125043.001]
  • [Cites] Virus Genes. 2006 Aug;33(1):107-16 [16791425.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):471-3 [11839854.001]
  • [Cites] Science. 2005 Jun 24;308(5730):1906-8 [15860590.001]
  • [Cites] Science. 1971 Nov 19;174(4011):840-3 [4330470.001]
  • [Cites] Clin Microbiol Rev. 1996 Jan;9(1):72-99 [8665478.001]
  • [Cites] Br J Rheumatol. 1993 Dec;32(12):1044-8 [8252311.001]
  • [Cites] Hepatology. 2004 Jan;39(1):151-6 [14752833.001]
  • [Cites] Arch Virol. 1985;85(3-4):197-207 [4026580.001]
  • [Cites] J Natl Cancer Inst. 1979 Aug;63(2):337-9 [287828.001]
  • [Cites] Cancer Immun. 2004 Feb 11;4:2 [14871062.001]
  • [Cites] Nature. 1977 Jul 28;268(5618):341-4 [196213.001]
  • [Cites] Clin Microbiol Infect. 1999 Feb;5(2):105-106 [11856228.001]
  • [Cites] J Virol. 1997 Apr;71(4):2866-72 [9060643.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1273-8 [10778951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1655-60 [17234809.001]
  • [Cites] J Virol. 2001 Apr;75(7):3089-94 [11238835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15687-92 [12429852.001]
  • [Cites] AIDS Res Hum Retroviruses. 2006 Jan;22(1):52-6 [16438646.001]
  • [Cites] Science. 1991 Aug 2;253(5019):555-7 [1650034.001]
  • [Cites] Mol Cell Biol. 2003 May;23(10):3566-74 [12724415.001]
  • [Cites] Genomics. 2005 Sep;86(3):337-41 [16024218.001]
  • [Cites] Placenta. 2005 Aug;26(7):556-62 [15993705.001]
  • [Cites] Science. 1989 Jan 27;243(4890):529-33 [2536193.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1544-8 [7509077.001]
  • [Cites] Res Virol. 1996 Nov-Dec;147(6):341-51 [8958587.001]
  • [Cites] Virus Res. 2007 Feb;123(2):211-5 [17005285.001]
  • [Cites] Cancer Res. 1970 Aug;30(8):2081-6 [4195910.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12841-6 [14534330.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):141-2 [11788827.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1622-6 [6246496.001]
  • [Cites] Mult Scler. 2003 Feb;9(1):6-15 [12617261.001]
  • [Cites] Cell. 1997 Jul 25;90(2):303-13 [9244304.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8454-9 [12832623.001]
  • [Cites] Acta Neurol Scand Suppl. 1997;169:16-21 [9174636.001]
  • [Cites] Cancer Res. 1983 Jan;43(1):239-44 [6291754.001]
  • [Cites] Biochim Biophys Acta. 1977 Mar 21;473(1):1-38 [66065.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):301-6 [12584181.001]
  • [Cites] J Virol. 2007 Jun;81(11):5607-16 [17360752.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Feb 10;15(3):285-91 [10052759.001]
  • [Cites] Cell. 1998 Oct 2;95(1):9-11; discussion 16 [9778241.001]
  • [Cites] Neurology. 1991 Mar;41(3):335-43 [1848687.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Apr;16(4):429-37 [9115754.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4417-9 [15240531.001]
  • [Cites] Neurosci Lett. 2006 Nov 20;408(3):226-9 [17000049.001]
  • [Cites] Placenta. 2007 Feb-Mar;28(2-3):185-91 [16714059.001]
  • [Cites] FEBS Lett. 1997 Aug 25;413(3):477-85 [9303559.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):493-501 [15300582.001]
  • [Cites] Cell. 1987 Oct 23;51(2):211-20 [2959371.001]
  • [Cites] Immunol Lett. 2002 Apr 1;81(1):87-91 [11841850.001]
  • [Cites] EMBO J. 1997 Nov 3;16(21):6590-602 [9351839.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):64-70 [10848783.001]
  • [Cites] Int J Cancer. 1979 Jan 15;23(1):1-7 [215558.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):351-5 [8090207.001]
  • [Cites] J Virol Methods. 1990 Apr;28(1):33-46 [1693369.001]
  • [Cites] Proc R Soc Med. 1965 May;58:295-300 [14283879.001]
  • [Cites] Cell. 1989 Jan 13;56(1):27-35 [2521300.001]
  • [Cites] J Virol. 1995 Oct;69(10):6408-16 [7545247.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]
  • [Cites] Lancet. 2002 Aug 3;360(9330):387-8 [12241782.001]
  • [Cites] J Virol. 2007 Apr;81(8):4130-6 [17287263.001]
  • [Cites] Science. 1991 Dec 20;254(5039):1808-10 [1722352.001]
  • [Cites] Virology. 1996 Mar 1;217(1):1-10 [8599193.001]
  • [Cites] J Virol. 1992 Apr;66(4):2170-9 [1548756.001]
  • [Cites] J Gen Virol. 2007 Jun;88(Pt 6):1806-9 [17485542.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2108-11 [10473094.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):914-23 [3127528.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1118-20 [12631616.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e25 [16609730.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Mar;70(3):859-62 [4123693.001]
  • [Cites] Melanoma Res. 2006 Jun;16(3):223-34 [16718269.001]
  • [Cites] J Gen Virol. 2004 May;85(Pt 5):1203-10 [15105536.001]
  • [Cites] Rheumatology (Oxford). 2001 Feb;40(2):227-8 [11257164.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1528-35 [12629516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13404-8 [10557333.001]
  • [Cites] Proc Natl Acad Sci U S A. 1972 Nov;69(11):3133-7 [4117770.001]
  • [Cites] Rev Med Virol. 2003 Sep-Oct;13(5):311-29 [12931341.001]
  • [Cites] Tokai J Exp Clin Med. 1990 May;15(2-3):219-25 [2130528.001]
  • [Cites] Nature. 1977 Feb 24;265(5596):687-95 [870828.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7284-9 [15534103.001]
  • [Cites] J Clin Microbiol. 1999 Nov;37(11):3545-55 [10523550.001]
  • [Cites] J Virol. 2003 Mar;77(6):3866-70 [12610163.001]
  • [Cites] PLoS Biol. 2003 Nov;1(2):E2 [14624234.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):971-80 [9064357.001]
  • [Cites] Science. 1989 Apr 21;244(4902):359-62 [2523562.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):1-10 [12925950.001]
  • [Cites] Virus Res. 2003 Aug;94(2):97-101 [12902038.001]
  • [Cites] Immunity. 2001 Oct;15(4):591-601 [11672541.001]
  • [Cites] Arthritis Rheum. 1992 Sep;35(9):1068-74 [1418023.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1367-72 [8891116.001]
  • [Cites] J Autoimmun. 1999 Aug;13(1):149-54 [10441180.001]
  • [Cites] Cancer Res. 1978 Oct;38(10):3123-39 [80259.001]
  • [Cites] Trends Microbiol. 1999 Nov;7(11):430; author reply 431-2 [10542419.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):304-7 [12397656.001]
  • [Cites] Science. 1989 Nov 10;246(4931):821-4 [2683085.001]
  • [Cites] Acta Neurol Scand. 1993 Feb;87(2):71-6 [8382893.001]
  • [Cites] J Neurovirol. 2005 Feb;11(1):23-33 [15804956.001]
  • [Cites] Int J Cancer. 2000 Mar 15;85(6):762-70 [10709092.001]
  • [Cites] Yale J Biol Med. 1976 May;49(2):175-95 [782050.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Dec;18(12):1321-8 [6299750.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 Oct 10;12(15):1473-83 [8893055.001]
  • [Cites] J Natl Cancer Inst. 1968 Jun;40(6):1359-73 [5660272.001]
  • [Cites] J Neuroimmunol. 2007 Jul;187(1-2):147-55 [17493688.001]
  • [Cites] Rheum Dis Clin North Am. 1992 Aug;18(3):683-97 [1496168.001]
  • [Cites] Curr Opin Neurol. 2007 Jun;20(3):261-8 [17495618.001]
  • [Cites] J Thorac Oncol. 2006 Nov;1(9 Suppl):S13-9 [17409995.001]
  • [Cites] Mol Biol Evol. 2002 Apr;19(4):526-33 [11919294.001]
  • [Cites] Nature. 1971 Feb 26;229(5287):611-4 [4925461.001]
  • [Cites] Cancer. 1980 Aug 15;46(4 Suppl):879-92 [6156755.001]
  • [Cites] J Gen Virol. 2000 Sep;81(Pt 9):2123-35 [10950968.001]
  • [Cites] Diabetologia. 1999 Apr;42(4):413-8 [10230644.001]
  • [Cites] Nature. 1991 Mar 21;350(6315):203-7 [1706480.001]
  • [Cites] Nucleic Acids Res. 1998 Apr 1;26(7):1628-35 [9512532.001]
  • [Cites] Ann Neurol. 1987 Jul;22(1):67-71 [2888429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12386-90 [12218182.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):785-9 [10693809.001]
  • [Cites] Cancer Res. 1978 Jun;38(6):1826-31 [206358.001]
  • [Cites] Virology. 1997 Oct 27;237(2):349-59 [9356346.001]
  • [Cites] J Gen Virol. 2001 Mar;82(Pt 3):591-6 [11172100.001]
  • [Cites] Res Virol. 1989 Nov-Dec;140(6):551-61 [2482522.001]
  • [Cites] Science. 1986 Jul 18;233(4761):343-6 [2425430.001]
  • [Cites] Genome Res. 2002 Mar;12(3):391-9 [11875026.001]
  • [Cites] J Immunol. 1990 Mar 1;144(5):1684-8 [1689754.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):862-3 [1707471.001]
  • [Cites] J Immunol. 2004 Oct 15;173(8):5121-9 [15470056.001]
  • [Cites] Acta Neurol Scand Suppl. 1997;169:22-31 [9174637.001]
  • [Cites] Intervirology. 1993;35(1-4):196-207 [8407246.001]
  • [Cites] Nat Med. 1998 Apr;4(4):403-7 [9546784.001]
  • [Cites] Microsc Res Tech. 2005 Nov;68(3-4):197-208 [16276516.001]
  • [Cites] J Lab Clin Med. 2000 Feb;135(2):139-44 [10695658.001]
  • [Cites] J Virol. 1999 Mar;73(3):2365-75 [9971820.001]
  • [Cites] J Virol. 2005 Dec;79(23):14737-47 [16282474.001]
  • [Cites] Virology. 1995 Aug 20;211(2):589-92 [7645262.001]
  • [Cites] Hum Genet. 2005 Sep;117(5):411-27 [15983781.001]
  • [Cites] Lancet. 1989 Apr 15;1(8642):814-7 [2468065.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):1531-5 [11591322.001]
  • [Cites] Mol Biol Evol. 2002 Nov;19(11):1934-42 [12411602.001]
  • [Cites] Nucleic Acids Res. 1989 Sep 12;17(17):6841-54 [2780312.001]
  • [Cites] Clin Microbiol Rev. 1996 Jan;9(1):18-33 [8665474.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Sep;6(9):1062-6 [8393488.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 7;93(21):1603-14 [11698564.001]
  • [Cites] J Gen Virol. 2001 Sep;82(Pt 9):2205-13 [11514731.001]
  • [Cites] J Neurovirol. 2003 Feb;9(1):79-93 [12587071.001]
  • [Cites] Leuk Lymphoma. 1993;11 Suppl 1:119-23 [7504541.001]
  • [Cites] Retrovirology. 2006;3:63 [16984654.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):459-61 [15095315.001]
  • [Cites] J Gen Virol. 1992 Sep;73 ( Pt 9):2463-6 [1402820.001]
  • [Cites] J Clin Pathol. 1997 Mar;50(3):223-30 [9155673.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1668-72 [14757818.001]
  • [Cites] J Natl Cancer Inst. 1972 Apr;48(4):1205-11 [4336885.001]
  • [Cites] N Engl J Med. 2001 Mar 1;344(9):655-64 [11228281.001]
  • [Cites] J Virol. 1999 Feb;73(2):1175-85 [9882319.001]
  • [Cites] J Virol. 1984 Jan;49(1):171-7 [6690709.001]
  • [Cites] J Neurovirol. 2003 Feb;9(1):112-7 [12587074.001]
  • [Cites] J Gen Virol. 1980 Apr;47(2):399-406 [6245177.001]
  • [Cites] Arthritis Rheum. 1992 Dec;35(12):1483-91 [1472125.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 May;8(5):742-51 [1381207.001]
  • [Cites] Int J Cancer. 1980 Jun 15;25(6):721-5 [14768700.001]
  • [Cites] Mol Genet Genomics. 2003 Dec;270(4):362-8 [14556071.001]
  • [Cites] Nat Rev Microbiol. 2007 Apr;5(4):253-63 [17325726.001]
  • [Cites] Clin Diagn Lab Immunol. 1999 Jan;6(1):115-26 [9874674.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):863-4 [1672959.001]
  • [Cites] Arthritis Rheum. 1999 Nov;42(11):2492-4 [10555048.001]
  • [Cites] PLoS Pathog. 2006 Dec;2(12):e128 [17140288.001]
  • [Cites] Int J Cancer. 1977 Apr 15;19(4):498-504 [403148.001]
  • [Cites] Nat New Biol. 1972 Jan 5;235(53):3-6 [4111969.001]
  • [Cites] Lancet. 1979 Aug 4;2(8136):258-9 [89378.001]
  • [Cites] Brain Pathol. 1992 Jan;2(1):61-9 [1341948.001]
  • [Cites] Lancet. 1992 Aug 1;340(8814):271-3 [1353193.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2348-55 [15571581.001]
  • [Cites] N Engl J Med. 1993 Feb 11;328(6):373-9 [8093633.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1939-43 [1347429.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 20;16(8):731-40 [10826480.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Apr;20(4):415-23 [15157360.001]
  • [Cites] Clin Orthop Relat Res. 1995 Apr;(313):239-52 [7543835.001]
  • [Cites] Oncogene. 2000 Sep 7;19(38):4328-36 [10980608.001]
  • [Cites] Retrovirology. 2005;2:50 [16092962.001]
  • [Cites] Ann Neurol. 1992 May;31(5):525-33 [1596089.001]
  • [Cites] Virology. 1995 Feb 20;207(1):217-28 [7871729.001]
  • [Cites] J Virol. 1992 Apr;66(4):1915-23 [1548748.001]
  • [Cites] Immunity. 2001 Oct;15(4):579-89 [11672540.001]
  • [Cites] Arthritis Rheum. 1986 May;29(5):577-85 [3718551.001]
  • [Cites] Cell Mol Life Sci. 2006 Aug;63(16):1906-11 [16871371.001]
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):366-81 [12878745.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):783-90 [11259092.001]
  • [Cites] J Virol. 2006 Jan;80(2):845-53 [16378986.001]
  • [Cites] Virology. 2003 Mar 30;308(1):1-12 [12706085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11117-22 [15263098.001]
  • [Cites] Genome Res. 2006 Dec;16(12):1548-56 [17077319.001]
  • [Cites] J Virol. 1995 Sep;69(9):5890-7 [7543594.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Jul;70(7):1976-80 [4124682.001]
  • [Cites] Virology. 2004 Jan 5;318(1):393-404 [14972564.001]
  • [Cites] Res Virol. 1992 Sep-Oct;143(5):337-50 [1282730.001]
  • [Cites] Biotechniques. 1996 Feb;20(2):210-7 [8825150.001]
  • [Cites] Virology. 1999 Jul 20;260(1):1-9 [10405350.001]
  • [Cites] J Virol. 2001 Mar;75(6):3053-7 [11222735.001]
  • [Cites] Virology. 1993 Sep;196(1):349-53 [8356806.001]
  • [Cites] Cell. 1998 Oct 2;95(1):11-4; discussion 16 [9778242.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2878-82 [2468159.001]
  • [Cites] J Gen Virol. 2003 Jan;84(Pt 1):215-25 [12533718.001]
  • [Cites] Arthritis Rheum. 1996 Aug;39(8):1410-8 [8702452.001]
  • [Cites] J Virol. 1999 Nov;73(11):9496-507 [10516058.001]
  • [Cites] Ann Trop Med Parasitol. 1998 Jan;92(1):97-105 [9614459.001]
  • [Cites] Science. 1991 Aug 30;253(5023):1026-8 [1887217.001]
  • [Cites] Trends Microbiol. 1999 Sep;7(9):350-6 [10470042.001]
  • [Cites] Microbes Infect. 1999 Apr;1(4):309-22 [10602665.001]
  • [Cites] Annu Rev Immunol. 1995;13:459-86 [7612231.001]
  • [Cites] Nat Med. 2004 Apr;10(4):368-73 [15034574.001]
  • [Cites] PLoS Pathog. 2007 Jan;3(1):e10 [17257061.001]
  • [Cites] J Virol. 2000 Jul;74(14):6386-93 [10864649.001]
  • [Cites] J Virol. 1988 Aug;62(8):2985-93 [2839715.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7583-8 [9207135.001]
  • [Cites] J Virol Methods. 1993 Feb;41(2):181-92 [7684387.001]
  • [Cites] Autoimmunity. 1995;20(2):135-42 [7578870.001]
  • [Cites] Clin Exp Immunol. 1997 Mar;107(3):474-9 [9067520.001]
  • [Cites] Science. 1975 Nov 7;190(4214):583-4 [810888.001]
  • [Cites] J Invest Dermatol. 1990 Nov;95(5):41S-43S [2230208.001]
  • [Cites] Oncogene. 2000 Aug 17;19(35):3988-98 [10962555.001]
  • [Cites] Ann Intern Med. 1989 Jul 15;111(2):158-67 [2662849.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3223-8 [15735668.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8735-41 [14695188.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1163-70 [8313318.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1553-60 [11410490.001]
  • [Cites] J Virol. 1993 Nov;67(11):6778-87 [7692084.001]
  • [Cites] PLoS Pathog. 2007 Nov;3(11):e165 [17997601.001]
  • [Cites] Science. 1999 Feb 19;283(5405):1171-6 [10024244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9 [15911757.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5177-84 [8643549.001]
  • [Cites] Cancer. 1971 Dec;28(6):1425-30 [5001818.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:149-73 [16722807.001]
  • [Cites] J Neural Transm (Vienna). 2007;114(5):645-55 [17219017.001]
  • [Cites] Nat Med. 2002 May;8(5):509-13 [11984596.001]
  • [Cites] Cancer Lett. 2007 Dec 8;258(1):22-30 [17889995.001]
  • [Cites] J Virol. 2004 Feb;78(4):2006-16 [14747565.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1754-9 [11245493.001]
  • [Cites] J Natl Cancer Inst. 1976 Aug;57(2):365-9 [187771.001]
  • [Cites] Br J Cancer. 1976 Aug;34(2):203-6 [183801.001]
  • [Cites] J Virol. 2006 Mar;80(6):2941-8 [16501103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jul;81(13):4188-92 [6330748.001]
  • [Cites] Science. 1983 May 20;220(4599):868-71 [6189183.001]
  • [Cites] Virus Res. 1999 May;61(1):19-27 [10426206.001]
  • [Cites] Diabetes. 1999 Jan;48(1):215-8 [9892247.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):953-6 [11461680.001]
  • [Cites] Virology. 2001 Jan 20;279(2):558-69 [11162811.001]
  • [Cites] Nature. 1988 May 5;333(6168):87-90 [2834650.001]
  • [Cites] Herpes. 2001 Nov;8(3):60-3 [11867021.001]
  • [Cites] Neurol Sci. 2001 Apr;22(2):179-85 [11603624.001]
  • [Cites] J Gen Virol. 2007 Jan;88(Pt 1):264-74 [17170460.001]
  • [Cites] J Virol. 1997 Jan;71(1):437-43 [8985368.001]
  • [Cites] Nature. 1972 Jan 7;235(5332):32-6 [4332799.001]
  • [Cites] Lancet. 1998 Sep 26;352(9133):1033 [9759750.001]
  • [Cites] Clin Microbiol Rev. 1993 Oct;6(4):382-427 [8269393.001]
  • [Cites] Ann N Y Acad Sci. 1957 Apr 19;67(8):430-8 [13411978.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2056-60 [16887963.001]
  • [Cites] Immunol Lett. 2001 Aug 1;78(1):51-4 [11470152.001]
  • [Cites] Retrovirology. 2006;3:44 [16822326.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):1866-71 [2112156.001]
  • [Cites] Retrovirology. 2005;2:30 [15882466.001]
  • [Cites] J Virol. 1991 Nov;65(11):5663-72 [1717707.001]
  • [Cites] Virology. 1995 Mar 10;207(2):577-82 [7886963.001]
  • [Cites] Infect Dis Clin North Am. 2006 Dec;20(4):913-29 [17118296.001]
  • [Cites] J Autoimmune Dis. 2006 Feb 19;3:1 [16504001.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1800-7 [12060620.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):293-6 [10207631.001]
  • [Cites] J Virol. 1989 Jan;63(1):64-75 [2462064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1731-6 [14757826.001]
  • [Cites] Virology. 2004 Oct 1;327(2):162-8 [15351203.001]
  • [Cites] Nature. 1972 Mar 17;236(5342):103-6 [4553539.001]
  • [Cites] Rev Med Virol. 2005 May-Jun;15(3):179-211 [15782388.001]
  • [Cites] J Virol. 1999 Nov;73(11):9187-95 [10516026.001]
  • [Cites] Neurology. 1990 Aug;40(8):1251-3 [2381534.001]
  • [Cites] J Virol. 2005 Jan;79(2):876-83 [15613316.001]
  • [Cites] Virology. 2001 Sep 1;287(2):321-32 [11531410.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand B. 1983 Aug;91(4):221-9 [6624461.001]
  • [Cites] Arch Virol. 1982;71(3):229-34 [6285859.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S3-6 [9849401.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2565-8 [9796992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10070-4 [1332028.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Mar;75(3):1529-33 [206905.001]
  • [Cites] Arthritis Rheum. 2006 Feb 15;55(1):123-5 [16463423.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):83-9 [16029331.001]
  • [Cites] AIDS Rev. 2004 Jul-Sep;6(3):144-54 [15595431.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):215-23 [17131333.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1039-42 [11679936.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6492-9 [15322520.001]
  • [Cites] Nucleic Acids Res. 2006;34(6):e46 [16554552.001]
  • [Cites] Nature. 1990 May 10;345(6271):120 [2159594.001]
  • [Cites] Science. 1973 Apr 15;180(4082):198-201 [4121027.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):680 [12152170.001]
  • [Cites] N Engl J Med. 1992 Jul 30;327(5):293-301 [1377787.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1658-63 [16452225.001]
  • [Cites] J Virol. 1987 Sep;61(9):2659-69 [3039159.001]
  • [Cites] Science. 1982 Nov 5;218(4572):571-3 [6981847.001]
  • [Cites] J Pathol. 2006 Aug;209(4):436-44 [16710841.001]
  • [Cites] J Virol. 2008 Feb;82(4):1808-18 [18077721.001]
  • [Cites] J Neurovirol. 2006 Feb;12(1):65-71 [16595376.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4362-5 [8813125.001]
  • [Cites] Lancet. 2001 Feb 3;357(9253):381-4 [11211014.001]
  • [Cites] Cancer. 1974 Oct;34(4 Suppl):suppl:1421-6 [4371153.001]
  • [Cites] J Exp Med. 1993 Aug 1;178(2):461-8 [7688023.001]
  • [Cites] Mol Cells. 2003 Feb 28;15(1):75-80 [12661764.001]
  • [Cites] J Virol. 2002 Jul;76(14):7094-102 [12072509.001]
  • [Cites] J Virol. 1996 Apr;70(4):2654-7 [8642702.001]
  • [Cites] J Natl Cancer Inst. 1974 Mar;52(3):987-9 [4363698.001]
  • [Cites] N Engl J Med. 1993 Feb 11;328(6):380-5 [8093634.001]
  • [Cites] J Virol Methods. 2001 May;94(1-2):187-93 [11337053.001]
  • [Cites] Acta Virol. 1977 Mar;21(2):139-45 [17282.001]
  • [Cites] Neurology. 1990 Aug;40(8):1254-8 [2381535.001]
  • [Cites] J Bacteriol. 1937 Jan;33(1):1-12 [16559982.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3341-5 [9096395.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 20;16(8):721-9 [10826479.001]
  • [Cites] Retrovirology. 2007;4:73 [17931409.001]
  • [Cites] N Engl J Med. 1988 Feb 18;318(7):448-9 [3422336.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):797-801 [11526389.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Dec;19(12):1105-13 [14709247.001]
  • [Cites] Arch Virol. 1985;86(1-2):37-45 [4038072.001]
  • [Cites] Intervirology. 1980;13(2):87-90 [6246030.001]
  • [Cites] Nucleic Acids Res. 1993 Jul 25;21(15):3593-4 [7688457.001]
  • [Cites] Nature. 1990 Jun 21;345(6277):659-60 [2163025.001]
  • [Cites] Biochemistry (Mosc). 1997 Nov;62(11):1202-5 [9467843.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4105-11 [15205319.001]
  • [Cites] Genomics. 1999 Oct 15;61(2):133-44 [10534399.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):992-1001 [10713682.001]
  • [Cites] J Virol. 2005 Dec;79(24):15573-7 [16306628.001]
  • [Cites] J Virol. 1986 Jun;58(3):937-44 [3009897.001]
  • [Cites] Arthritis Rheum. 1999 Mar;42(3):448-54 [10088767.001]
  • [Cites] Curr Top Microbiol Immunol. 2003;275:225-48 [12596901.001]
  • [Cites] Vet Immunol Immunopathol. 1998 Feb 27;61(2-4):229-37 [9613437.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Diabetologia. 2000 Dec;43(12):1484-97 [11151757.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Jan;11(1):161-70 [7734189.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] Blood. 2002 May 1;99(9):3335-41 [11964301.001]
  • [Cites] Ann Hematol. 2001 Nov;80(11):669-73 [11757726.001]
  • [Cites] Diabetes. 1999 Jan;48(1):209-14 [9892246.001]
  • [Cites] J Natl Cancer Inst. 1974 Mar;52(3):975-7 [4133196.001]
  • [Cites] Arthritis Rheum. 1990 Jun;33(6):774-81 [2363733.001]
  • [Cites] Clin Orthop Relat Res. 1996 May;(326):287-309 [8620655.001]
  • (PMID = 18322038.001).
  • [ISSN] 1098-5557
  • [Journal-full-title] Microbiology and molecular biology reviews : MMBR
  • [ISO-abbreviation] Microbiol. Mol. Biol. Rev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G8712499; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 547
  • [Other-IDs] NLM/ PMC2268285
  •  go-up   go-down


34. Castillo J, Hansen C, Mega A, Tashima K: AIDS-related lymphomas: the Rhode Island experience. Med Health R I; 2008 Nov;91(11):332-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas: the Rhode Island experience.
  • [MeSH-major] Lymphoma, AIDS-Related

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093379.001).
  • [ISSN] 1086-5462
  • [Journal-full-title] Medicine and health, Rhode Island
  • [ISO-abbreviation] Med Health R I
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ: Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci; 2007 Oct;334(4):317-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric Castleman's disease masquerading as HIV-related lymphoma.
  • Patients with human immunodeficiency virus (HIV) infection are at increased risk for developing lymphoproliferative disorders.
  • Multicentric Castleman's disease should always be kept in the differential diagnosis of HIV-positive patients suspected of having lymphoma to avoid misdiagnosis.
  • We report the case of a 40-year-old HIV-positive homosexual man who presented with lower back pain and features highly suggestive of lymphoma including lymphadenopathy, elevated lactic dehydrogenase, and splenomegaly.
  • The patient's plasma was positive by polymerase chain reaction for Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/ HHV8), and a lymph node biopsy revealed Multicentric Castleman's disease.
  • Albeit a rare condition, Castleman's disease should always be considered in immunocompromised patients suspected of having lymphoma.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Lymphoma, AIDS-Related / diagnosis


36. Rafaniello Raviele P, Pruneri G, Maiorano E: Plasmablastic lymphoma: a review. Oral Dis; 2009 Jan;15(1):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: a review.
  • Plasmablastic lymphoma (PBL) has been recently characterised as an aggressive subtype of non-Hodgkin's lymphoma, most frequently arising in the oral cavity of HIV-infected patients.
  • Similar to other types of AIDS-related lymphomas, there is evidence that Epstein-Barr virus and Kaposi-sarcoma associated Human Herpes Virus 8 may play a relevant role in the pathogenesis of PBL.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939960.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / SDC1 protein, human; 0 / Syndecan-1
  • [Number-of-references] 54
  •  go-up   go-down


37. Verma N, Chaudhary UB, Costa LJ, Gudena V, Lazarchick J: Primary testicular lymphoma and AIDS. Ann Clin Lab Sci; 2010;40(1):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma and AIDS.
  • Immunosuppressed patients have an increased risk for developing extranodal lymphoma, including testicular lymphoma.
  • In AIDS patients, primary testicular lymphoma has been reported as an initial manifestation of the disease.
  • These patients typically present at an early age; their lymphomas usually have aggressive histologic appearance and are associated with poor prognosis.
  • We report a testicular lymphoma consistent with diffuse large B-cell lymphoma (DLBCL) in an AIDS patient and we review the literature on primary testicular lymphoma in AIDS patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology


38. Carbone A, Gloghini A: AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol; 2005 Sep;130(5):662-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas: from pathogenesis to pathology.
  • Human immunodeficiency virus (HIV)-associated lymphomas include:.
  • (1) lymphomas also occurring, although sporadically, in the absence of HIV infection.
  • The vast majority of these lymphomas are high-grade B-cell lymphomas: Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) with centroblastic (CB) features and DLBCL with immunoblastic (IBL) features;.
  • (2) unusual lymphomas occurring more specifically in HIV-positive patients and include two rare entities, namely 'primary effusion lymphoma' (PEL) and 'plasmablastic lymphoma' of the oral cavity.
  • The pathological heterogeneity of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas (AIDS-NHL) reflects the heterogeneity of their associated molecular lesions.
  • In AIDS-BL, the molecular lesions involve activation of cMYC, inactivation of P53, and infection with Epstein-Barr virus (EBV).
  • AIDS-IBL infected with EBV are characterised by frequent expression of latent membrane protein 1--an EBV oncoprotein.
  • The biological heterogeneity of AIDS-NHL is highlighted by their histogenetic differences.
  • Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8)-associated lymphomas, which often develop in persons with advanced AIDS, present predominantly as PEL.
  • KSHV/HHV8 has also been recently detected in solid extracavitary-based lymphomas.
  • The KSHV/HHV8-associated solid lymphomas are (1) unusual lymphomas that occur more specifically in HIV-positive patients;.
  • (2) extracavitary and arise in nodal and/or extranodal sites; and (3) histologically, they usually display a PEL-like morphology and plasma cell-related phenotype.
  • [MeSH-major] HIV-1. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin. Sarcoma, Kaposi


39. Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL: Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis; 2008 Apr;8(4):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection.
  • Plasmablastic lymphoma of the oral cavity is a form of non-Hodgkin lymphoma (NHL) and was first described in 1997.
  • We describe a case of plasmablastic lymphoma in an HIV-infected patient who presented with an expanding oral lesion and symptoms of a toothache.
  • We review all cases of plasmablastic lymphoma that have been reported in the literature.
  • Plasmablastic lymphoma is strongly associated with immunodeficiency, and most particularly, with HIV infection.
  • The pathophysiological origin of plasmablastic lymphoma has not been fully characterised, but the presence of Epstein-Barr virus (EBV) has often been documented in biopsy specimens, supporting a role for EBV in the pathogenesis of this lymphoma.
  • Infectious disease clinicians should be aware of this newly described and increasingly encountered lymphoma, since it is prominently associated with immunosuppression and may be mistaken for other entities.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Mouth / pathology. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Head / radiography. Humans. Male. Tomography, X-Ray Computed. Toothache / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Lancet Infect Dis. 2010 Apr;10(4):226
  • (PMID = 18353267.001).
  • [ISSN] 1473-3099
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


40. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G: High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood; 2009 Aug 13;114(7):1306-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
  • After the introduction of highly active antiretroviral therapy (HAART), intensive treatment, including high-dose therapy (HDT) and peripheral blood stem cell transplantation (PBSCT), has become feasible in HIV-positive patients with Hodgkin (HL) and non-Hodgkin (NHL) lymphoma.
  • Herein, we report the long-term results, on an intention-to-treat basis, of a prospective study on HDT and PBSCT in 50 HIV-positive HAART-responding patients with refractory/relapsed lymphoma.
  • After debulking therapy, 2 patients had early toxic deaths, 10 had chemoresistant disease, 6 failed stem cell mobilization, 1 refused collection, and 4 progressed soon after PBSC harvest.
  • Twenty-one patients are alive and disease-free after a median follow-up of 44 months (OS, 74.6%; PFS, 75.9%).
  • Only lymphoma response significantly affected OS after transplantation.
  • In multivariate analyses both lymphoma stage and low CD4 count negatively influenced the possibility to receive transplant.
  • PBSCT is a highly effective salvage treatment for chemosensitive AIDS-related lymphoma.
  • It seems rational to explore its use earlier during the course of lymphoma to increase the proportion of patients who can actually receive transplant.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / therapy. Antiretroviral Therapy, Highly Active. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy. Male. Middle Aged. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous


41. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ: Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood; 2005 Jan 15;105(2):874-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas.
  • The treatment of HIV-associated lymphoma has changed since the widespread use of highly active antiretroviral therapy.
  • HIV-infected individuals can tolerate more intensive chemotherapy, as they have better hematologic reserves and fewer infections.
  • This has led to higher response rates in patients with HIV-associated Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) treated with chemotherapy in conjunction with antiretroviral therapy.
  • However, for patients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-term survival.
  • In the non-HIV setting, patients with relapsed Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) have a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue (ASCT) compared with conventional salvage chemotherapy.
  • In a prior report we demonstrated that this approach is well tolerated in patients with underlying immunodeficiency from HIV infection.
  • Furthermore, similar engraftment to the non-HIV setting and low infectious risks have been observed.
  • With long-term follow-up we demonstrate that ASCT can lead to an 85% progression-free survival, which suggests that this approach may be potentially curative in select patients with relapsed HIV-associated HD or NHL.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. CD4 Lymphocyte Count. Child. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Recurrence. Remission Induction. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15388574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI38592; United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / CA33572
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


42. Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A, European Group for Blood and Marrow Transplantation Lymphoma Working Party: Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood; 2009 Jun 4;113(23):6011-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.
  • Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on highly active antiretroviral therapy.
  • We report the first comparative analysis between HIV-Ly and a matched cohort of HIV(-) lymphoma patients.
  • This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin lymphoma) within each cohort.
  • Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin lymphoma and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the HIV-Ly cohort.
  • A higher nonrelapse mortality within the first year after ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival.
  • Thus, within the highly active antiretroviral therapy era, HIV patients should be considered for ASCT according to the same criteria adopted for HIV(-) lymphoma patients.
  • [MeSH-major] HIV Infections / surgery. Hodgkin Disease / surgery. Peripheral Blood Stem Cell Transplantation


43. Shapira A, Benhar I: Toxin-based therapeutic approaches. Toxins (Basel); 2010 11;2(11):2519-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxin-based therapeutic approaches.
  • Protein toxins confer a defense against predation/grazing or a superior pathogenic competence upon the producing organism.
  • Such toxins have been perfected through evolution in poisonous animals/plants and pathogenic bacteria.
  • Over the past five decades, a lot of effort has been invested in studying their mechanism of action, the way they contribute to pathogenicity and in the development of antidotes that neutralize their action.
  • In parallel, many research groups turned to explore the pharmaceutical potential of such toxins when they are used to efficiently impair essential cellular processes and/or damage the integrity of their target cells.
  • The following review summarizes major advances in the field of toxin based therapeutics and offers a comprehensive description of the mode of action of each applied toxin.
  • [MeSH-major] Pharmaceutical Preparations. Plant Extracts / therapeutic use. Plants, Toxic / chemistry. Toxins, Biological / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Bacterial Toxins / therapeutic use. Biological Evolution. Cell Death / genetics. Drug Evaluation, Preclinical. Female. Genes, Transgenic, Suicide. Genetic Therapy / methods. Humans. Immunotoxins / therapeutic use. Male

  • MedlinePlus Health Information. consumer health - Medicines.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2006 Dec 15;177(12):8822-34 [17142785.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):473-80 [18469827.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2590-5 [8653702.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):693-700 [10690555.001]
  • [Cites] Cell Res. 2007 Feb;17(2):89-99 [17242688.001]
  • [Cites] Curr Pharm Des. 2009;15(23):2652-64 [19689336.001]
  • [Cites] Ann N Y Acad Sci. 1976;277(00):690-9 [187103.001]
  • [Cites] Am J Obstet Gynecol. 1997 Sep;177(3):579-85 [9322627.001]
  • [Cites] Leuk Lymphoma. 1993 Nov;11(5-6):369-77 [8124209.001]
  • [Cites] Nature. 1991 Apr 18;350(6319):625-6 [2017258.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):789-94 [8703804.001]
  • [Cites] Annu Rev Med. 2007;58:221-37 [17059365.001]
  • [Cites] Biochem J. 1983 Jun 1;211(3):575-87 [6882361.001]
  • [Cites] Curr Drug Targets. 2006 Oct;7(10):1301-11 [17073592.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7049-53 [11997439.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1589-94 [9815960.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3654-61 [9345050.001]
  • [Cites] Cell. 1987 Jan 16;48(1):129-36 [3098436.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):773-84 [17346030.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Mol Aspects Med. 2009 Dec;30(6):413-22 [19563824.001]
  • [Cites] Gene Ther. 2005 Oct;12(19):1415-6 [17243198.001]
  • [Cites] PLoS Pathog. 2010 Mar;6(3):e1000792 [20221438.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Aug;10(8):552-60 [15282533.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3693-701 [10845899.001]
  • [Cites] J Biol Chem. 1982 Apr 25;257(8):4147-51 [7068628.001]
  • [Cites] Biochim Biophys Acta. 1986 Oct 16;868(1):62-70 [3756169.001]
  • [Cites] Phytopathology. 2003 May;93(5):588-95 [18942981.001]
  • [Cites] J Cell Biol. 2003 Mar 31;160(7):1139-50 [12668662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14701-6 [9405676.001]
  • [Cites] Int J Med Microbiol. 2009 Mar;299(3):161-76 [18948059.001]
  • [Cites] J Biol Chem. 1993 Feb 15;268(5):3334-41 [8429009.001]
  • [Cites] Mini Rev Med Chem. 2004 Jun;4(5):505-12 [15180507.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):3-13 [14649881.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3218-24 [10866314.001]
  • [Cites] FEBS Lett. 1997 Apr 7;406(1-2):162-4 [9109409.001]
  • [Cites] Biochemistry. 1998 Nov 10;37(45):15737-46 [9843379.001]
  • [Cites] Nature. 1992 May 21;357(6375):216-22 [1589020.001]
  • [Cites] Int J Biochem Cell Biol. 2009 May;41(5):1055-61 [18935973.001]
  • [Cites] J Biol Chem. 1994 Aug 12;269(32):20607-12 [8051159.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2576-82 [11980652.001]
  • [Cites] Br J Haematol. 2010 Aug;150(3):352-8 [20528877.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Infect Immun. 1994 Feb;62(2):333-40 [8300195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8548-53 [10890891.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 Jan;8(1):39-45 [1736939.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5287-97 [19738110.001]
  • [Cites] Blood. 1987 Mar;69(3):836-40 [3101766.001]
  • [Cites] Curr Pharm Des. 2009;15(31):3671-80 [19925419.001]
  • [Cites] FEBS Lett. 2002 Nov 20;531(3):384-8 [12435580.001]
  • [Cites] Int J Med Microbiol. 2002 Feb;291(6-7):517-21 [11890552.001]
  • [Cites] Annu Rev Plant Physiol Plant Mol Biol. 2001 Jun;52:785-816 [11337416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4528-32 [2034693.001]
  • [Cites] Gene Ther. 2010 Sep;17(9):1063-76 [20410930.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2102-10 [17051247.001]
  • [Cites] Mol Microbiol. 1997 Feb;23(3):445-57 [9044279.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1297-304 [9607590.001]
  • [Cites] Oncol Rep. 1998 May-Jun;5(3):673-7 [9538174.001]
  • [Cites] J Biol Chem. 1990 Nov 25;265(33):20673-7 [2243114.001]
  • [Cites] J Clin Invest. 2003 Sep;112(5):670-82 [12952916.001]
  • [Cites] Microbes Infect. 2003 Sep;5(11):1023-7 [12941394.001]
  • [Cites] Clin Med Res. 2006 Sep;4(3):218-27 [16988102.001]
  • [Cites] Carbohydr Res. 1997 May 16;300(3):251-8 [9202409.001]
  • [Cites] Curr Control Trials Cardiovasc Med. 2000;1(2):120-127 [11714424.001]
  • [Cites] AIDS Rev. 2002 Jan-Mar;4(1):41-9 [11998784.001]
  • [Cites] Cell Mol Life Sci. 2004 Apr;61(7-8):873-85 [15095009.001]
  • [Cites] BioDrugs. 2009;23(1):1-13 [19344187.001]
  • [Cites] J Immunol. 1999 Dec 1;163(11):6072-7 [10570296.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1260-2 [14641038.001]
  • [Cites] Curr Drug Targets. 2009 Feb;10(2):89-93 [19199903.001]
  • [Cites] Toxicon. 2005 Mar 15;45(4):475-80 [15733569.001]
  • [Cites] Isr Med Assoc J. 2001 Jul;3(7):517-22 [11791420.001]
  • [Cites] J Immunol. 1987 Sep 15;139(6):2081-7 [3040864.001]
  • [Cites] Cancer Lett. 2008 Nov 8;270(2):191-201 [18502571.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20810-5 [19106292.001]
  • [Cites] J Biol Chem. 1992 Dec 15;267(35):25396-401 [1460035.001]
  • [Cites] N Engl J Med. 2001 Jul 26;345(4):241-7 [11474661.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1315-6 [20167707.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1227-31 [7999404.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):29261-6 [12724328.001]
  • [Cites] Curr Opin Biotechnol. 1994 Oct;5(5):511-5 [7765465.001]
  • [Cites] Blood. 1997 Jan 15;89(2):403-10 [9002941.001]
  • [Cites] Curr Med Chem. 2002 Nov;9(21):1893-903 [12369874.001]
  • [Cites] Pathol Annu. 1989;24 Pt 2:149-65 [2671880.001]
  • [Cites] Cancer Gene Ther. 2005 May;12(5):449-55 [15706354.001]
  • [Cites] J Biol Response Mod. 1988 Feb;7(1):97-113 [3373237.001]
  • [Cites] Curr Pharm Des. 2007;13(3):333-46 [17313364.001]
  • [Cites] J Biol Chem. 1980 Jul 25;255(14):6947-53 [7391060.001]
  • [Cites] Annu Rev Microbiol. 2008;62:271-88 [18785839.001]
  • [Cites] Plant Mol Biol. 2000 Jul;43(4):439-50 [11052196.001]
  • [Cites] Biochim Biophys Acta. 1997 Apr 24;1356(2):185-97 [9150276.001]
  • [Cites] Trends Cell Biol. 2007 Apr;17(4):165-72 [17306546.001]
  • [Cites] Int J Technol Assess Health Care. 2002 Summer;18(3):645-74 [12391957.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2527-9 [15928038.001]
  • [Cites] Somat Cell Mol Genet. 2001 Nov;26(1-6):13-33 [12465460.001]
  • [Cites] Oncogene. 1995 Mar 16;10(6):1193-8 [7700644.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):27-35 [14649883.001]
  • [Cites] Infect Immun. 1992 Feb;60(2):497-502 [1730481.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):7-11 [10428315.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5274-9 [19671873.001]
  • [Cites] Arthritis Rheum. 1993 May;36(5):620-30 [7683881.001]
  • [Cites] Mol Pathol. 1997 Feb;50(1):34-44 [9208812.001]
  • [Cites] J Biol Chem. 1990 Nov 25;265(33):20678-85 [2122978.001]
  • [Cites] Toxicology. 1994 Feb 28;87(1-3):29-41 [7512762.001]
  • [Cites] J Neurosurg. 1990 Jun;72(6):941-5 [2159987.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R617-26 [16168106.001]
  • [Cites] Mol Microbiol. 2010 May;76(4):1010-9 [20398220.001]
  • [Cites] Genes Cells. 1997 Jan;2(1):13-28 [9112437.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Mini Rev Med Chem. 2004 Jun;4(5):545-62 [15180510.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18167-76 [8027078.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1610-9 [16818521.001]
  • [Cites] J Pathol. 1987 Mar;151(3):221-9 [3572616.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):551-4 [12576417.001]
  • [Cites] J Biol Chem. 1979 Oct 10;254(19):9795-9 [489569.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4660-4 [3460697.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):165-71 [7556146.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 4):467-75 [9914159.001]
  • [Cites] J Biomed Biotechnol. 2003;2003(2):138-148 [12721517.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1319-30 [19897580.001]
  • [Cites] World J Gastroenterol. 1998 Oct;4(5):388-391 [11819328.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Mar;11(3):188-93 [15744237.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2143-8 [15161668.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Jan;5(1):87-103 [18095930.001]
  • [Cites] Ann Oncol. 2003 May;14(5):729-36 [12702527.001]
  • [Cites] J Appl Microbiol. 1999 Aug;87(2):289-93 [10475971.001]
  • [Cites] Cell Mol Life Sci. 2006 Aug;63(16):1850-66 [16799768.001]
  • [Cites] Cancer Control. 2000 Jul-Aug;7(4):335-9 [10895127.001]
  • [Cites] Annu Rev Biochem. 2007;76:243-65 [17335404.001]
  • [Cites] Microbes Infect. 2004 Jul;6(8):786-9 [15207826.001]
  • [Cites] J Urol. 1996 Jun;155(6):2120-7 [8618347.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):267-75 [15739554.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2599-604 [9829722.001]
  • [Cites] Biochim Biophys Acta. 1981 Nov 5;677(3-4):495-500 [7295807.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):376-81 [16000956.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Aug;78(8):4950-4 [6272284.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7045-8 [11997437.001]
  • [Cites] J Biol Chem. 1992 Jun 25;267(18):12420-3 [1618748.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):90-6 [15701286.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 10;258(2):252-5 [10329373.001]
  • [Cites] Biochemistry. 1997 Nov 25;36(47):14577-82 [9398176.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1779-86 [12060617.001]
  • [Cites] Biochem J. 1997 Oct 15;327 ( Pt 2):413-7 [9359409.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1173-82 [1878584.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):18-24 [10094809.001]
  • [Cites] Mol Pathol. 1998 Feb;51(1):21-5 [9624415.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):57-61 [9815887.001]
  • [Cites] J Immunol. 1981 Apr;126(4):1398-403 [6451645.001]
  • [Cites] Science. 2005 Jul 29;309(5735):777-81 [16051798.001]
  • [Cites] J Appl Microbiol. 1999 Aug;87(2):288 [10475970.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):287-97 [15781315.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):17976-84 [11278833.001]
  • [Cites] Biochim Biophys Acta. 2004 Sep 1;1701(1-2):1-14 [15450171.001]
  • [Cites] Annu Rev Med. 2002;53:437-52 [11818484.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1302-13 [10778955.001]
  • [Cites] Biochem J. 1995 Apr 1;307 ( Pt 1):29-37 [7717988.001]
  • [Cites] J Biol Chem. 1990 Jul 15;265(20):11885-9 [2195027.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 May;79(10):3162-6 [6285339.001]
  • [Cites] Neurotox Res. 2006 Apr;9(2-3):63-71 [16785102.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Jan;78(1):172-6 [6264431.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):4062-7 [2786751.001]
  • [Cites] Obstet Gynecol Surv. 2007 Oct;62(10):675-9; quiz 691 [17868483.001]
  • [Cites] J Clin Invest. 1985 Nov;76(5):1899-903 [3902893.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30439-46 [16908524.001]
  • [Cites] Biochem J. 2000 Dec 15;352 Pt 3:739-45 [11104681.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 13;270(2):453-7 [10753646.001]
  • [Cites] Nucleic Acids Res. 2010 Oct;38(19):6803-12 [20558598.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] Nucleic Acids Res. 1997 Feb 1;25(3):518-22 [9016590.001]
  • [Cites] J Biol Response Mod. 1990 Aug;9(4):345-54 [2395000.001]
  • [Cites] Trends Mol Med. 2007 Oct;13(10):443-8 [17913584.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 25;16(4):1349-57 [3347493.001]
  • [Cites] Infect Immun. 2007 Jan;75(1):417-28 [17101666.001]
  • [Cites] Hum Immunol. 2004 Aug;65(8):794-802 [15336780.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):679-90 [18698327.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):480-2 [8564957.001]
  • [Cites] Biochim Biophys Acta. 1985 Jun 18;840(2):193-203 [3922431.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4095-102 [15353540.001]
  • [Cites] Mol Aspects Med. 1994;15(2):79-193 [7984032.001]
  • [Cites] Angiogenesis. 2003;6(1):31-8 [14517402.001]
  • [Cites] Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984;17:189-98 [6328915.001]
  • [Cites] Oncologist. 1997;2(5):324-329 [10388065.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Sep;9(6):555-66 [19732003.001]
  • [Cites] Annu Rev Immunol. 1997;15:481-504 [9143697.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):554-71 [19394376.001]
  • [Cites] Virol J. 2006;3:26 [16603059.001]
  • [Cites] Arch Dermatol. 2002 Jun;138(6):740-2 [12056952.001]
  • [Cites] J Immunol. 1992 Sep 15;149(6):2089-94 [1517572.001]
  • [Cites] Blood. 1997 Jul 1;90(1):252-9 [9207460.001]
  • [Cites] Mutat Res. 2001 Jun 2;477(1-2):97-110 [11376691.001]
  • [Cites] Exp Dermatol. 2003 Dec;12(6):799-810 [14714561.001]
  • [Cites] Science. 1998 May 1;280(5364):734-7 [9563949.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jan;196(1):7-15 [17240220.001]
  • [Cites] J Immunol. 1987 May 1;138(9):2793-9 [2437199.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3555-61 [14506141.001]
  • [Cites] J Vet Med Sci. 1997 Jul;59(7):617-9 [9271462.001]
  • [Cites] Biochem J. 1975 Jan;146(1):127-31 [167711.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:45-70 [14570563.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(12):2880-8 [18611444.001]
  • [Cites] Biochem J. 2004 Jan 1;377(Pt 1):233-40 [13129434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16028-33 [15520369.001]
  • [Cites] Postgrad Med J. 2004 Oct;80(948):560-70 [15466989.001]
  • [Cites] J Am Acad Dermatol. 2001 Dec;45(6):871-81 [11712032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3783-8 [9108055.001]
  • [Cites] Am J Pathol. 1987 Mar;126(3):506-12 [3103454.001]
  • [Cites] Arthritis Rheum. 1995 Sep;38(9):1177-86 [7575710.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7437-43 [17189417.001]
  • [Cites] J Biol Chem. 1986 Jun 15;261(17):7912-20 [3711116.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):723-34 [9053498.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):201-7 [8471594.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2010 Jan;37(1):108-14 [19671071.001]
  • [Cites] EMBO J. 2005 Mar 9;24(5):929-41 [15719022.001]
  • [Cites] Chem Rev. 2002 Dec;102(12):4609-26 [12475203.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10277-81 [1438214.001]
  • [Cites] Apoptosis. 2004 Jan;9(1):19-25 [14739595.001]
  • [Cites] Plant Mol Biol. 1997 Dec;35(6):701-9 [9426592.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:93-103 [14531567.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4299-304 [1868451.001]
  • [Cites] Immunopharmacology. 1997 Oct;37(2-3):117-32 [9403331.001]
  • [Cites] N Engl J Med. 1992 Jul 2;327(1):14-8 [1317941.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):541-8 [15234235.001]
  • [Cites] Blood. 1994 Jan 15;83(2):426-34 [8286741.001]
  • [Cites] FEBS J. 2007 Sep;274(18):4825-36 [17714513.001]
  • [Cites] Exp Cell Res. 1993 Mar;205(1):118-25 [8453986.001]
  • [Cites] Immunity. 2000 Jul;13(1):117-27 [10933400.001]
  • [Cites] Infect Immun. 2007 May;75(5):2201-7 [17296757.001]
  • [Cites] J Exp Bot. 2004 Oct;55(406):2219-33 [15333641.001]
  • [Cites] EMBO J. 1993 Feb;12(2):677-82 [8440258.001]
  • [Cites] Mol Microbiol. 1993 Nov;10(3):647-53 [7968541.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):231-41 [8680651.001]
  • [Cites] Cancer Drug Deliv. 1986 Summer;3(3):189-96 [3490901.001]
  • [Cites] Nature. 2003 Jul 17;424(6946):329-34 [12867985.001]
  • [Cites] Breast Cancer Res Treat. 2003 Dec;82(3):155-64 [14703062.001]
  • [Cites] Pharmacology. 2008;82(3):171-9 [18679046.001]
  • [Cites] Br J Cancer. 2009 Oct 6;101(7):1114-23 [19755995.001]
  • [Cites] Nat Genet. 1994 Jul;7(3):433-9 [7920665.001]
  • [Cites] Int J Biochem Cell Biol. 2000 May;32(5):571-7 [10736572.001]
  • [Cites] Clin Exp Immunol. 1989 Feb;75(2):258-64 [2784738.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):396-402 [11807546.001]
  • [Cites] Lancet. 1992 May 16;339(8803):1195-6 [1349939.001]
  • [Cites] World J Urol. 1993;11(4):188-91 [7508781.001]
  • [Cites] Cancer Res. 1987 Feb 15;47(4):947-52 [3492271.001]
  • [Cites] J Rheumatol. 1994 Nov;21(11):2068-70 [7532717.001]
  • [Cites] J Neural Transm (Vienna). 2008;115(4):559-65 [17458494.001]
  • [Cites] Handb Exp Pharmacol. 2010;(197):143-70 [20217529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5170-4 [12700348.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2083-90 [10232592.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):937-47 [15573115.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):837-44 [17327604.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9402-6 [12522135.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12142-9 [8901547.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):645-50 [11920631.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6153-60 [2790828.001]
  • [Cites] J Virol. 1995 Nov;69(11):7180-6 [7474139.001]
  • [Cites] Mol Aspects Med. 2009 Dec;30(6):431-8 [19665472.001]
  • [Cites] FASEB J. 2002 Mar;16(3):365-72 [11874985.001]
  • [Cites] J Biol Chem. 1987 Jun 25;262(18):8707-11 [2885323.001]
  • [Cites] J Vet Med Sci. 1997 Mar;59(3):169-74 [9101475.001]
  • [Cites] Arch Biochem Biophys. 2005 Feb 15;434(2):258-65 [15639225.001]
  • [Cites] Mol Med Today. 1999 Oct;5(10):448-53 [10498913.001]
  • [Cites] Blut. 1990 Mar;60(3):181-6 [2180499.001]
  • [Cites] Annu Rev Med. 2009;60:139-51 [18947298.001]
  • [Cites] FASEB J. 1999 May;13(8):781-92 [10224222.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6061-7 [11085528.001]
  • [Cites] J Biol Chem. 1989 Aug 25;264(24):14256-61 [2503515.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:105-11 [14531568.001]
  • [Cites] Infect Immun. 1977 Jan;15(1):138-44 [188760.001]
  • [Cites] Leukemia. 2000 Jan;14(1):129-35 [10637488.001]
  • [Cites] Cancer Gene Ther. 1994 Dec;1(4):279-87 [7543006.001]
  • [Cites] Biochim Biophys Acta. 2006 May;1760(5):783-92 [16564632.001]
  • [Cites] Hum Gene Ther. 2002 Mar 1;13(4):533-42 [11874631.001]
  • [Cites] EMBO J. 1998 Jan 15;17(2):615-25 [9430652.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2009 Jan 27;364(1514):209-15 [18957378.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1303-10 [16170021.001]
  • [Cites] Carbohydr Res. 1996 Mar 18;282(2):285-92 [8901091.001]
  • [Cites] Blood. 1993 Aug 15;82(4):1277-87 [7688993.001]
  • [Cites] FEBS Lett. 1999 Jun 4;452(1-2):67-70 [10376680.001]
  • [Cites] Mol Aspects Med. 2009 Dec;30(6):406-12 [19732789.001]
  • [Cites] J Virol. 2007 Jul;81(13):6947-56 [17442709.001]
  • [Cites] Plant Physiol. 2004 Jan;134(1):171-81 [14671015.001]
  • [Cites] Nat Biotechnol. 2003 Apr;21(4):372-4 [12665820.001]
  • [Cites] J Immunol. 1981 Apr;126(4):1393-7 [6970774.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3781-7 [1648444.001]
  • [Cites] FEBS Lett. 1999 Nov 26;462(1-2):199-204 [10580119.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7750-3 [2253218.001]
  • [Cites] Leuk Lymphoma. 1997 Jul;26(3-4):287-98 [9322891.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2095-103 [1960550.001]
  • [Cites] Mol Microbiol. 1995 Feb;15(4):661-6 [7783638.001]
  • [Cites] J Biol Chem. 2008 Jan 4;283(1):529-40 [17974567.001]
  • [Cites] Toxicon. 2004 Sep 15;44(4):371-83 [15302521.001]
  • [Cites] Cancer Treat Rev. 2008 Apr;34(2):122-36 [18162327.001]
  • [Cites] Int J Cancer Suppl. 1994;8:57-9 [7515030.001]
  • [Cites] BioDrugs. 2008;22(5):301-14 [18778112.001]
  • [Cites] Nat Biotechnol. 2005 Jun;23(6):725-30 [15895075.001]
  • [Cites] Am J Clin Oncol. 2009 Jun;32(3):269-73 [19433964.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):677-85 [11257099.001]
  • [Cites] Biotechnol J. 2009 Nov;4(11):1559-72 [19844918.001]
  • [Cites] Biol Chem Hoppe Seyler. 1995 Nov;376(11):637-41 [8962672.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Jun;72(6):2284-8 [166383.001]
  • [Cites] Protein Expr Purif. 1997 Jun;10(1):27-31 [9179286.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 Feb;8(2):291-5 [1540415.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3930-4 [8358720.001]
  • [Cites] Cancer Gene Ther. 2003 Oct;10(10):764-70 [14502229.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):349-55 [8903477.001]
  • [Cites] J Biol Chem. 1988 Jun 25;263(18):8735-9 [3288622.001]
  • [Cites] Biochemistry. 2002 Mar 12;41(10):3405-13 [11876649.001]
  • [Cites] Urology. 1995 Feb;45(2):335-8 [7855987.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5940-4 [7597057.001]
  • [Cites] Cancer Res. 1988 May 1;48(9):2618-25 [3258546.001]
  • [Cites] Prostate. 2007 Jun 1;67(8):855-62 [17427200.001]
  • [Cites] J Biomed Biotechnol. 2003;2003(2):110-137 [12721516.001]
  • [Cites] Curr Drug Targets. 2009 Feb;10(2):104-9 [19199905.001]
  • [Cites] Endocr Relat Cancer. 2002 Jun;9(2):115-39 [12121835.001]
  • [Cites] J Immunol. 1985 Mar;134(3):1524-30 [3918103.001]
  • [Cites] Cell. 1978 Sep;15(1):245-50 [699044.001]
  • [Cites] Blood. 1997 Sep 1;90(5):2020-6 [9292538.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2311-5 [10499598.001]
  • [Cites] Traffic. 2006 Apr;7(4):379-93 [16536737.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2624-33 [8219217.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41 [19875969.001]
  • [Cites] DNA Repair (Amst). 2005 Feb 3;4(2):271-7 [15590335.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31399-406 [10906135.001]
  • [Cites] Nucleic Acids Res. 1999 Apr 15;27(8):1900-5 [10101199.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2556-62 [17041100.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Immunol. 1997 Nov 15;159(10):5168-73 [9366448.001]
  • [Cites] Biotechnol Lett. 2007 Oct;29(10):1605-10 [17579811.001]
  • [Cites] Prostate. 1990;17(1):31-40 [1696713.001]
  • [Cites] Clin Exp Immunol. 1992 Sep;89(3):341-6 [1516253.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1717-23 [3493066.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1584-90 [19039293.001]
  • [Cites] Cancer Res. 1991 Aug 1;51(15):4052-8 [1855219.001]
  • [Cites] Hum Gene Ther. 1992 Oct;3(5):461-9 [1329991.001]
  • [Cites] J Biol Chem. 1991 Dec 5;266(34):23422-7 [1744135.001]
  • [Cites] CA Cancer J Clin. 2010 Jul-Aug;60(4):244-72 [20566675.001]
  • [Cites] Mol Vis. 2005;11:1101-11 [16379022.001]
  • [Cites] Clin Cancer Res. 2010 Mar 15;16(6):1894-903 [20215554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3052-7 [11867750.001]
  • [Cites] J Neurosurg. 1989 Feb;70(2):240-8 [2783608.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1995;60:461-78 [8824420.001]
  • [Cites] Mini Rev Med Chem. 2004 Jun;4(5):563-83 [15180511.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):525-37 [9711915.001]
  • [Cites] Dig Dis Sci. 2000 Jun;45(6):1045-52 [10877214.001]
  • [Cites] Cell Cycle. 2008 Mar 15;7(6):745-9 [18245947.001]
  • [Cites] Semin Cancer Biol. 1995 Oct;6(5):269-78 [8562904.001]
  • [Cites] J Cell Mol Med. 2005 Apr-Jun;9(2):267-85 [15963249.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1466-75 [11920503.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):321-8 [12551953.001]
  • [Cites] Biochemistry. 1994 May 17;33(19):5894-900 [8180218.001]
  • [Cites] Mini Rev Med Chem. 2004 Jun;4(5):461-76 [15180503.001]
  • [Cites] RNA. 2000 Mar;6(3):369-80 [10744021.001]
  • [Cites] FEBS Lett. 1999 Oct 1;459(1):80-4 [10508921.001]
  • [Cites] Mini Rev Med Chem. 2004 Jun;4(5):523-43 [15180509.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4919-28 [17878392.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):37201-7 [15205454.001]
  • [Cites] Cancer. 2006 May 15;106(10):2158-64 [16586495.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):174-81 [10729833.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1039-49; discussion 1049-51 [9361057.001]
  • [Cites] J Clin Immunol. 2007 Jan;27(1):1-18 [17216565.001]
  • [Cites] Plant J. 1994 Dec;6(6):815-24 [7849755.001]
  • [Cites] J Urol. 2008 Dec;180(6):2379-83 [18950807.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):327-33 [17080335.001]
  • [Cites] J Mol Biol. 2006 Feb 3;355(5):968-79 [16343527.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3329-36 [17409442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6 [18678888.001]
  • [Cites] Curr Gene Ther. 2009 Jun;9(3):185-91 [19519363.001]
  • [Cites] J Biochem. 2000 Nov;128(5):883-9 [11056402.001]
  • [Cites] J Reprod Immunol. 2010 May;85(1):93-8 [20227765.001]
  • [Cites] J Natl Cancer Inst. 1989 May 10;81(10):775-81 [2785605.001]
  • [Cites] Blood. 1993 May 1;81(9):2263-71 [8481509.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):145-9 [10102343.001]
  • [Cites] J Biosci. 2005 Jun;30(3):351-7 [16052073.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6719-29 [16061911.001]
  • [Cites] Eur J Biochem. 1990 Oct 24;193(2):401-7 [2226460.001]
  • [Cites] Drug Discov Today. 2008 Sep;13(17-18):807-15 [18678276.001]
  • [Cites] Blood. 1992 May 15;79(10):2547-54 [1586707.001]
  • [Cites] Gene. 1999 Mar 18;229(1-2):101-8 [10095109.001]
  • [Cites] Curr Opin Mol Ther. 2000 Aug;2(4):433-40 [11249774.001]
  • [Cites] Life Sci. 1996;59(22):1853-9 [8950282.001]
  • [Cites] Clin Immunol. 2000 Apr;95(1 Pt 2):S39-43 [10729236.001]
  • [Cites] Mol Cancer Res. 2009 Apr;7(4):452-61 [19372576.001]
  • [Cites] Nat Med. 1996 Mar;2(3):350-3 [8612238.001]
  • [Cites] FEBS Lett. 2003 Mar 13;538(1-3):178-82 [12633875.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Apr;34(4):396-402 [11854038.001]
  • [Cites] Mol Ther. 2002 Oct;6(4):537-45 [12377196.001]
  • [Cites] Biochim Biophys Acta. 1972 May 9;266(2):543-7 [4338881.001]
  • [Cites] Semin Cancer Biol. 1995 Oct;6(5):307-17 [8562908.001]
  • [Cites] Cancer Gene Ther. 2010 Jan;17(1):58-68 [19609296.001]
  • [Cites] Immunol Invest. 2006;35(1):93-114 [16531332.001]
  • [Cites] Plant Cell. 1992 Feb;4(2):225-34 [1633495.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):423-30 [8570220.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):125-37 [12952293.001]
  • [Cites] J Biol Chem. 1992 Aug 5;267(22):15542-8 [1639793.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26461-5 [8253774.001]
  • [Cites] J Drug Target. 2000;8(5):281-8 [11328656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5254-9 [18356299.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4813-20 [12466280.001]
  • [Cites] Neurotox Res. 2007 Dec;12(4):275-90 [18201955.001]
  • [Cites] Nat Biotechnol. 2003 Apr;21(4):387-91 [12627168.001]
  • [Cites] FEBS Lett. 1996 Mar 18;382(3):309-12 [8605991.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4219-25 [1868442.001]
  • [Cites] Nature. 1974 Oct 18;251(5476):628-30 [4417936.001]
  • [Cites] Leukemia. 1988 Apr;2(4):211-5 [2834611.001]
  • [Cites] Int Rev Cytol. 1974;39:89-190 [4611947.001]
  • [Cites] Leuk Lymphoma. 1994 Jul;14(3-4):257-62 [7950914.001]
  • [Cites] Eur J Biochem. 1997 Apr 15;245(2):316-23 [9151959.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Dec;291(3):1301-7 [10565855.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):968-75 [9500458.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):726-37 [7683045.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1553-61 [3510728.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):365-76 [16781083.001]
  • [Cites] Nature. 2001 Nov 8;414(6860):225-9 [11700562.001]
  • [Cites] Biochemistry. 1997 Sep 16;36(37):11051-4 [9333321.001]
  • [Cites] Curr HIV Res. 2009 Jan;7(1):91-100 [19149558.001]
  • [Cites] FEBS J. 2005 Oct;272(19):4983-95 [16176271.001]
  • [Cites] Mol Cancer Ther. 2010 Jan;9(1):190-201 [20053778.001]
  • [Cites] J Transl Med. 2009;7:69 [19656414.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3457-65 [7780133.001]
  • [Cites] Int J Cancer. 1989 Feb 15;43(2):215-9 [2465276.001]
  • [Cites] Curr Pharm Des. 2006;12(11):1301-14 [16611117.001]
  • [Cites] Biochem J. 2004 Oct 15;383(Pt 2):285-93 [15225124.001]
  • [Cites] J Cataract Refract Surg. 1998 Dec;24(12):1614-20 [9850900.001]
  • [Cites] Mol Ther. 2000 Dec;2(6):539-44 [11124054.001]
  • [Cites] Eur J Pharm Biopharm. 2009 Mar;71(3):475-83 [18955136.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):343-50 [10760695.001]
  • [Cites] Hum Gene Ther. 1991 Spring;2(1):53-60 [1863640.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7774-8 [8356083.001]
  • [Cites] Cell. 2001 Sep 21;106(6):661-73 [11572773.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):406-12 [8621218.001]
  • [Cites] Biochem Pharmacol. 2005 Mar 1;69(5):855-65 [15710362.001]
  • [Cites] Hum Gene Ther. 1993 Dec;4(6):741-7 [8186289.001]
  • [Cites] Int Rev Immunol. 2001;20(6):739-62 [11913948.001]
  • [Cites] Mol Biother. 1991 Dec;3(4):192-6 [1768370.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):89-96 [16432166.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1004-13 [12006512.001]
  • [Cites] Int J Cancer. 1988 Nov 15;42(5):792-7 [3263328.001]
  • [Cites] Blood. 1998 Jan 15;91(2):399-405 [9427692.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):36334-40 [10926933.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1622-36 [10764422.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2392-8 [10499609.001]
  • [Cites] Cell Biochem Funct. 2005 Jul-Aug;23(4):223-7 [15473004.001]
  • [Cites] Hum Gene Ther. 1995 Nov;6(11):1437-45 [8573616.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1188-97 [8695836.001]
  • [Cites] Blood. 1990 Apr 1;75(7):1426-32 [2180494.001]
  • [Cites] J Infect Dis. 1974 Nov;130 Suppl(0):S94-9 [4370620.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1870-7 [20212249.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):320-9 [18403491.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34443-9 [10567425.001]
  • [Cites] J Mol Med (Berl). 1996 Jul;74(7):379-92 [8841950.001]
  • [Cites] IDrugs. 1998 Aug;1(4):476-9 [18465581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7012-6 [8041737.001]
  • [Cites] Mol Biother. 1990 Jun;2(2):104-9 [2363853.001]
  • [Cites] Gene Regul Syst Bio. 2007 Dec 11;1:313-25 [19936097.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(7):2209-13 [2467303.001]
  • [Cites] J Cataract Refract Surg. 2000 May;26(5):716-21 [10831902.001]
  • [Cites] Biochem J. 1989 Feb 1;257(3):723-7 [2930482.001]
  • [Cites] Biochemistry. 1999 Dec 14;38(50):16507-13 [10600112.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3092-9 [12374676.001]
  • [Cites] Semin Immunol. 1998 Aug;10(4):267-77 [9695183.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5798-806 [16740719.001]
  • [Cites] Biochemistry (Mosc). 2008 Mar;73(3):273-7 [18393761.001]
  • [Cites] Cancer Drug Deliv. 1987;4(4):245-53 [3502618.001]
  • [Cites] Pathophysiol Haemost Thromb. 2008;36(3-4):184-94 [19176991.001]
  • [Cites] Gene Ther. 2001 Sep;8(18):1416-26 [11571582.001]
  • [Cites] Cell Microbiol. 2000 Jun;2(3):251-8 [11207581.001]
  • [Cites] JAMA. 1988 Jun 3;259(21):3154-7 [3285046.001]
  • [Cites] Nat Cell Biol. 2003 May;5(5):373-6 [12724766.001]
  • [Cites] Science. 1970 Jul 3;169(3940):68-70 [4986716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):861-5 [12576460.001]
  • [Cites] J Diabetes Complications. 1993 Oct-Dec;7(4):224-32 [7693056.001]
  • [Cites] Biochem J. 1999 Oct 1;343 Pt 1:199-207 [10493930.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3957-62 [10097145.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2616-23 [16794252.001]
  • [Cites] Science. 1987 Oct 23;238(4826):536-9 [3498987.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):2983-90 [19414673.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Clin Microbiol Rev. 1998 Oct;11(4):614-27 [9767059.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2048-51 [12202685.001]
  • [Cites] Semin Cancer Biol. 2000 Dec;10(6):415-33 [11170864.001]
  • [Cites] Nucleic Acids Res. 1991 Nov 25;19(22):6309-12 [1659689.001]
  • [Cites] J Immunol. 1993 Jun 1;150(11):4715-8 [8496586.001]
  • [Cites] AAPS J. 2006;8(3):E532-51 [17025272.001]
  • [Cites] Blood. 1986 Jun;67(6):1680-7 [3085747.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1276-85 [8313331.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):189-93 [11125087.001]
  • [Cites] Mol Ther. 2005 Feb;11(2):196-204 [15668131.001]
  • [Cites] Br J Haematol. 1993 Nov;85(3):435-8 [8136262.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 14;1480(1-2):258-66 [10899626.001]
  • [Cites] Methods Mol Biol. 2010;651:157-75 [20686966.001]
  • [Cites] FEBS Lett. 1986 Feb 17;196(2):344-8 [3949006.001]
  • [Cites] J Cell Biol. 2004 Aug 30;166(5):645-51 [15337774.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):47-56 [14751137.001]
  • [Cites] Oncol Rep. 2009 May;21(5):1323-33 [19360311.001]
  • [Cites] Biochem J. 1991 Aug 1;277 ( Pt 3):855-61 [1908224.001]
  • [Cites] J Exp Bot. 2005 Jun;56(416):1675-84 [15863448.001]
  • [Cites] Expert Opin Biol Ther. 2004 Jul;4(7):1115-28 [15268678.001]
  • [Cites] Am J Clin Oncol. 1995 Aug;18(4):307-12 [7625372.001]
  • [Cites] J Med Case Rep. 2010 Jul 27;4:228 [20663201.001]
  • [Cites] Ann Ist Super Sanita. 2010;46(1):5-14 [20348614.001]
  • [Cites] Gene Ther. 2005 Nov;12(21):1573-80 [16034457.001]
  • [Cites] FEBS Lett. 1996 Aug 19;392(1):16-20 [8769306.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Curr Opin Cell Biol. 2000 Aug;12(4):407-13 [10873820.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):657-62 [12525700.001]
  • [Cites] Chin Med J (Engl). 1998 May;111(5):404-7 [10374347.001]
  • [Cites] J Am Acad Dermatol. 1998 Jun;38(6 Pt 1):938-44 [9632001.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6184-91 [19643734.001]
  • [Cites] Jpn J Cancer Res. 1990 Sep;81(9):902-8 [2121691.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):436S-439S [8384975.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Feb 15;150(3):1032-6 [3342056.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):7150-6 [11120846.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2083-7 [2566368.001]
  • [Cites] Neuro Oncol. 2010 Aug;12(8):871-81 [20511192.001]
  • [Cites] J Rheumatol. 1994 Apr;21(4):596-604 [7518519.001]
  • [Cites] Eur J Biochem. 1986 Feb 17;155(1):1-10 [3948873.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):308-12 [2104981.001]
  • [Cites] Arthritis Rheum. 1996 Jul;39(7):1102-8 [8670317.001]
  • [Cites] FASEB J. 2001 Jul;15(9):1493-506 [11427481.001]
  • (PMID = 22069564.001).
  • [ISSN] 2072-6651
  • [Journal-full-title] Toxins
  • [ISO-abbreviation] Toxins (Basel)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bacterial Toxins; 0 / Immunotoxins; 0 / Pharmaceutical Preparations; 0 / Plant Extracts; 0 / Toxins, Biological
  • [Other-IDs] NLM/ PMC3153180
  • [Keywords] NOTNLM ; anthrax (major topic) / diphtheria toxin (major topic) / immunotoxins (major topic) / pseudomonas exotoxin A (major topic) / ricin (major topic) / suicide gene (major topic) / targeting (major topic) / toxins (major topic)
  • [General-notes] NLM/ Original DateCompleted: 20111110
  •  go-up   go-down


44. Wong KH, Lee SS, Chan KC: Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong. Hong Kong Med J; 2006 Apr;12(2):133-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong.
  • OBJECTIVE: To elucidate the development of human immunodeficiency virus (HIV) clinical care and research in Hong Kong.
  • DATA SOURCES: Articles on clinical HIV and acquired immunodeficiency syndrome (AIDS) published from 1985 to 2004 were identified through four sources: Red Ribbon Centre, Special Preventive Programme, Secretariat of the Scientific Committee on AIDS, and PubMed search.
  • STUDY SELECTION: Key words for the literature search were 'AIDS', 'HIV', and 'Hong Kong'.
  • The contents were catalogued under seven areas: clinical epidemiology, HIV disease course and presentation, specific complications or organ-based manifestations, immunological evaluation and other monitoring, antiretroviral therapy, HIV/AIDS mortality, and HIV in specific groups.
  • Prevalence of HIV has remained low in Hong Kong but new infections continue to occur together with a significant number of late presenters.
  • Three published AIDS patients' series, up to the first 200 reported cases, identified Pneumocystis carinii pneumonia as the most common AIDS-defining illness in Hong Kong.
  • Local studies of Kaposi's sarcoma and HIV-associated lymphoma have also been reported.
  • Research on CD4 counts has revealed that it is lower in healthy and HIV-infected Chinese than their western counterparts.
  • Children, pregnant women, and haemophiliac patients infected with HIV are among the specific groups of patients studied.
  • Survival of patients with advanced disease has greatly improved over the years, particularly after the advent of highly active antiretroviral therapy.
  • CONCLUSION: The clinical presentation and outcome of HIV/AIDS patients in Hong Kong are a mixture of those of western and developing countries.
  • Research on clinical HIV/AIDS in Hong Kong is not only beneficial to the planning of patient care, but also enables the formulation of treatment guidelines and provides a reference for other countries.


45. Krishnan A, Forman SJ: Hematopoietic stem cell transplantation for AIDS-related malignancies. Curr Opin Oncol; 2010 Sep;22(5):456-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for AIDS-related malignancies.
  • PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection.
  • In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies.
  • Prior to the advent of effective HIV therapy, stem cell transplantation was not feasible for HIV-positive patients.
  • The purpose of this article is to explore the transplant options for HIV-positive patients after widespread use of highly active antiretroviral therapy.
  • RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients.
  • Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions.
  • In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival.
  • The feasibility of allogeneic stem cell transplantation in HIV-infected individuals is less tested.
  • SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • (PMID = 20639760.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS427480; NLM/ PMC3537514
  •  go-up   go-down


46. Fellner MD, Durand K, Correa RM, Redini L, Yampolsky C, Colobraro A, Sevlever G, Teyssié AR, Benetucci J, Picconi MA: Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis; 2007 Mar;11(2):172-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma.
  • OBJECTIVE: To analyze Epstein-Barr virus (EBV) load at different HIV infection stages and its relation with brain lymphoma.
  • DESIGN: A cross-sectional study was conducted on 172 HIV-infected individuals: 62 asymptomatic HIV carriers (group A), 30 HIV progressors (group B), 73 AIDS patients (group C), seven AIDS patients with brain lymphoma (group C-BL); and 26 blood donors (group BD) as healthy carriers.
  • RESULTS: PBMC-EBV levels in HIV-infected patients were higher than in the blood donors (p<0.05).
  • Similar PBMC-EBV loads were seen in HIV-infected patients with CD4+ T cell counts higher than 50/mm(3) (p>0.05), while significantly lower levels were found in cases with less than 50 cells/mm(3) (p<0.05).
  • In all HIV-infected patients, plasma-EBV load was lower than, or similar to, PBMC-EBV load, unlike 2/7 HIV-positive brain lymphoma patients.
  • CONCLUSIONS: During HIV infection PBMC-EBV load rises in comparison to healthy carriers, but decreases when immunosuppression progresses and CD4+ T cell count becomes <50/mm(3).
  • Circulating EBV is mainly cell-associated in the HIV-infected population.
  • Neither PBMC-EBV nor plasma-EBV loads would be useful to diagnose brain lymphoma in AIDS patients.
  • [MeSH-major] Brain Neoplasms / virology. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931088.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


47. Miles SA, McGratten M: Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol; 2005 Jan 1;23(1):247-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
  • [MeSH-major] Agammaglobulinemia / chemically induced. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625386.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


48. Noy A: Controversies in the treatment of Burkitt lymphoma in AIDS. Curr Opin Oncol; 2010 Sep;22(5):443-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the treatment of Burkitt lymphoma in AIDS.
  • PURPOSE OF REVIEW: The success of combined antiretroviral therapy (cART) has transformed HIV infection into a survivable chronic disease in developed countries.
  • Increasingly then, the risks of HIV associated cancers become paramount.
  • Burkitt lymphoma is one of the cancer subtypes highly disproportionately affecting HIV infected patients.
  • RECENT FINDINGS: Recent conference proceedings appear to corroborate early reports that intensive therapy of HIV-Burkitt lymphoma is feasible and effective.
  • Moreover, as breakthroughs in the pathogenesis of lymphoma in general and Burkitt lymphoma in particular suggest that HIV infection plays a significant role, the opportunity for targeted therapy based on differences in biology are wholly untapped.
  • SUMMARY: Advances are being made in HIV-Burkitt lymphoma, but future studies need to incorporate our expanding understanding of biology to improve efficacy and reduce toxicity, preferably by integrating a biologic approach to this curable disease.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1492-9 [11920506.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):475-8 [14617009.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):667-76 [14770420.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Med Clin North Am. 1992 Jan;76(1):253-68 [1727539.001]
  • [Cites] Am J Clin Pathol. 1995 May;103(5):561-7 [7741100.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):33-9; discussion 45-8 [9578060.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1755-66 [18596745.001]
  • [Cites] Leukemia. 2009 Apr;23(4):807-10 [18987659.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):462-8 [19620863.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Aug;9(4):307-10 [19717381.001]
  • [Cites] Swiss Med Wkly. 2009 Oct 3;139(39-40):564-70 [19838874.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Jan;53(1):124-30 [19730109.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):245-55 [19832807.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1732-9 [19810101.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3008-16 [20023215.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3017-24 [20130244.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • (PMID = 20683266.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121947-03S4; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / U01 CA121947-03S4
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Other-IDs] NLM/ NIHMS237420; NLM/ PMC3415038
  •  go-up   go-down


49. Wagner-Johnston ND, Ambinder RF: Blood and marrow transplant for lymphoma patients with HIV/AIDS. Curr Opin Oncol; 2008 Mar;20(2):201-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood and marrow transplant for lymphoma patients with HIV/AIDS.
  • PURPOSE OF REVIEW: Important strides in the management of patients with HIV/AIDS-related lymphomas have been made in recent years.
  • This review will discuss the role of bone marrow or peripheral stem-cell transplantation as a modality for patients with HIV and lymphoma.
  • RECENT FINDINGS: In the era of highly active antiretroviral therapy, patients with HIV-associated lymphoma are generally being treated with standard or only slightly modified chemotherapy regimens.
  • Autologous bone marrow and stem-cell transplant approaches in lymphoma patients have been successful.
  • Case reports suggest that allogeneic transplantation for patients with HIV and hematologic malignancies merits further investigation.
  • [MeSH-major] Bone Marrow Transplantation. HIV Infections / complications. HIV Infections / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / therapy. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):289-90 [10969356.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]
  • [Cites] Exp Hematol. 2002 Mar;30(3):279-84 [11882366.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4423-7 [14581441.001]
  • [Cites] Haematologica. 2004 Sep;89(9):1100-8 [15377471.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2943-6 [15238428.001]
  • [Cites] J Clin Oncol. 1987 Sep;5(9):1322-8 [2442321.001]
  • [Cites] Ann Intern Med. 1989 Dec 15;111(12):973-81 [2512828.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4299-306 [9192752.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1891-7 [15550484.001]
  • [Cites] Exp Hematol. 2005 Apr;33(4):487-94 [15781340.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(3):261-2 [15908966.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Acta Haematol. 2005;114(4):188-97 [16269858.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1560-8 [16502436.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Haematologica. 2007 Feb;92(2):191-8 [17296568.001]
  • [Cites] Haematologica. 2007 Apr;92(4):e56-8 [17562594.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):416-21 [11744828.001]
  • (PMID = 18300771.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA096888; United States / NCI NIH HHS / CA / R01 CA095423
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  • [Other-IDs] NLM/ NIHMS281898; NLM/ PMC4138614
  •  go-up   go-down


50. Latta S, Myint ZW, Jallad B, Hamdi T, Alhosaini MN, Kumar DV, Kheir F: Primary central nervous system T-cell lymphoma in aids patients: case report and literature review. Curr Oncol; 2010 Oct;17(5):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system T-cell lymphoma in aids patients: case report and literature review.
  • According to the published data, most primary central nervous system lymphomas (PCNSLs) are B-cell lymphomas; primary T-cell lymphomas are rare.
  • Here, we present the case of a 43-year-old man with AIDS, not on highly active antiretroviral therapy, who presented with focal neurologic symptoms and was found on magnetic resonance imaging to have multiple brain lesions.
  • A biopsy showed T-cell lymphoma, and the patient was subsequently treated with whole-brain radiation, to marked clinical response.
  • Reported cases from the literature of primary T-cell PCNSL in AIDS patients are summarized in this review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975881.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2949374
  • [Keywords] NOTNLM ; Primary cns lymphoma / T cells / aids / non-Hodgkin lymphoma
  •  go-up   go-down


51. Dupéré-Minier G, Desharnais P, Bernier J: Involvement of tyrosine phosphatase CD45 in apoptosis. Apoptosis; 2010 Jan;15(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, it is involved in apoptosis induced by HIV-1.
  • CD45 defect is implicated in various diseases such as severe-combined immunodeficiency disease (SCID), acquired immunodeficiency syndrome (AIDS), lymphoma and multiple myelomas.
  • The understanding of the mechanisms by which CD45 regulates apoptosis would be very useful in disease treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856105.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


52. Stevenson GT: CD38 as a therapeutic target. Mol Med; 2006 Nov-Dec;12(11-12):345-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Humans. Leukemia / immunology. Lymphoma, B-Cell / immunology. Mice. Mice, SCID. Multiple Myeloma / immunology. Transplantation, Heterologous

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Jan;25(1):1-12 [11137554.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):345-52 [15026555.001]
  • [Cites] Scand J Immunol. 1978 Apr;7(4):297-306 [418499.001]
  • [Cites] Am J Hematol. 1990 Feb;33(2):101-9 [2301368.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1071-9 [1995092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):352-6 [8380497.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1442-9 [7520771.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3017-25 [7524764.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):455-63 [16920192.001]
  • (PMID = 17380203.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ PMC1829201
  •  go-up   go-down


53. Dawson MA, Schwarer AP, McLean C, Oei P, Campbell LJ, Wright E, Shortt J, Street AM: AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica; 2007 Jan;92(1):e11-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
  • Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases.
  • In part this has been due to limited insights into the biology of this disease and the molecular mechanisms of oncogenesis.
  • To date molecular abnormalities have not been described in plasmablastic lymphoma, and its aggressive clinical behaviour has been difficult to understand.
  • We describe the first reported cytogenetic abnormality in plasmablastic lymphoma, an IgH/MYC translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Genes, myc. Gingival Neoplasms / genetics. Hemophilia A / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Large-Cell, Immunoblastic / genetics. Peripheral Blood Stem Cell Transplantation. Translocation, Genetic


54. Tulpule A: Multidrug resistance in AIDS-related lymphoma. Curr Opin Oncol; 2005 Sep;17(5):466-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance in AIDS-related lymphoma.
  • PURPOSE OF REVIEW: AIDS-related lymphoma has a decreased response rate and poorer prognosis to standard chemotherapy when compared with lymphoma in the non-HIV population.
  • In addition to the known HIV-related and lymphoma-related poor prognostic factors, this review discusses another factor, MDR-1 expression and its impact on response to therapy in patients with AIDS-related lymphoma.
  • RECENT FINDINGS: There is an increased incidence of de-novo MDR-1 expression in AIDS-related lymphoma compared with lymphoma in the non-HIV settings.
  • MDR-1 expression in AIDS-related lymphoma is associated with poor response to conventional combination chemotherapy.
  • Liposomal encapsulation of doxorubicin when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) seems to overcome P-glycoprotein-mediated drug resistance in AIDS-related lymphoma.
  • SUMMARY: The overexpression of MDR-1 gene product P-glycoprotein is an adverse prognostic factor in AIDS-related lymphoma.
  • Treatment with liposomal encapsulated doxorubicin seems to overcome the P-glycoprotein-related drug resistance.
  • This and other strategies to modulate MDR-1 should be further explored in order to improve success rates in the treatment of AIDS-related lymphoma.
  • [MeSH-major] Drug Resistance, Multiple, Viral / genetics. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / genetics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093797.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 23
  •  go-up   go-down


55. Serrano D, Carrión R, Balsalobre P, Miralles P, Berenguer J, Buño I, Gómez-Pineda A, Ribera JM, Conde E, Díez-Martín JL, Spanish Cooperative Groups GELTAMO and GESIDA: HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol; 2005 Apr;33(4):487-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation.
  • OBJECTIVE: To evaluate feasibility, safety, and efficacy of peripheral blood stem cell collection (PBSCC) and autologous stem cell transplantation (ASCT), to treat patients diagnosed of high-risk or relapsed HIV-associated lymphoma (HIV+ Ly), responding to highly active antiretroviral therapy (HAART).
  • METHODS: Prospective and multicentric study in patients with high-risk or relapsed chemosensitive HIV+ Ly, candidate for consolidation with ASCT.
  • Eligibility criteria were similar to those of HIV- lymphoma.
  • Three patients died before ASCT; two had disease progression and one died from VHC-liver failure.
  • CD4+ cell counts and HIV viral load (VL) were appropriately preserved along the procedure.
  • No patients died from treatment-related complications.
  • One patient died from lymphoma progression (day +19), and another died in complete remission (CR) with undetectable VL, 15 months after transplant, due to infection.
  • CONCLUSIONS: These results show that feasibility, safety, and efficacy of PBSCC and ASCT in HIV+ Ly patients responding to HAART are similar to those observed in the HIV- lymphoma setting.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Peripheral Blood Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781340.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


56. Scheper MA, Nikitakis NG, Fernandes R, Gocke CD, Ord RA, Sauk JJ: Oral plasmablastic lymphoma in an HIV-negative patient: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Aug;100(2):198-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral plasmablastic lymphoma in an HIV-negative patient: a case report and review of the literature.
  • Plasmablastic lymphoma is an HIV-associated non-Hodgkin's lymphoma that primarily affects the oral cavity and jaws.
  • The purpose of this report is to describe the first case of plasmablastic lymphoma occurring in an HIV-negative, nonimmunocompromised individual, and to review the histopathologic and immunohistochemical phenotype of this lymphoma.
  • The features of this rare disease are summarized based on a comprehensive review of the epidemiologic, clinical and immunohistochemical findings of previously reported cases.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mandibular Neoplasms / pathology
  • [MeSH-minor] HIV Seronegativity. Humans. Immunoglobulin G / analysis. Immunoglobulin lambda-Chains / analysis. Immunohistochemistry. Male. Middle Aged. Plasma Cells. Viral Matrix Proteins / analysis

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16037778.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Immunoglobulin G; 0 / Immunoglobulin lambda-Chains; 0 / Viral Matrix Proteins
  • [Number-of-references] 29
  •  go-up   go-down


57. Jacobson MA: Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS? PLoS Med; 2007 Mar 27;4(3):e110
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS?
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. CD4-Positive T-Lymphocytes / cytology. CD4-Positive T-Lymphocytes / virology. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / virology. HIV Infections / complications. Lymphoma / complications. Lymphoma / virology
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Case-Control Studies. Chronic Disease. HLA Antigens / metabolism. Haplotypes. Herpesvirus 4, Human / metabolism. Humans. Prospective Studies


58. Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martínez-Maza O: Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol; 2006;27(4):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.
  • CD30, first described as the Ki antigen on malignant B cells in Hodgkin's lymphoma, is also expressed on normal activated B and T cells.
  • In a cross-sectional study utilizing archived sera at a time point close to but preceding a diagnosis of acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin's B cell lymphoma, AIDS lymphoma subjects (n = 49) showed elevated mean levels of sCD30 compared to controls with AIDS but no malignancy (n = 44, p < 0.01), HIV-infected but relatively healthy (n = 47, p < 0.001), or HIV-seronegative controls (n = 44, p < 0.001).
  • Serum sCD30 was significantly correlated to serum levels of the B cell cytokines interleukin-6 (IL-6), IL-10, and sCD23, but only among lymphoma subjects (p < or = 0.05).
  • Correlations between sCD30 and other markers of immune system activation were seen among all HIV-infected subjects (sCD27, sCD44, CXCL13, p < 0.05).
  • These observations suggest that sCD30, especially in combination with other immune system molecules, could be an important biomarker for an immune system environment conducive to B cell hyperactivation and the development of AIDS-associated B cell lymphoma.
  • [MeSH-major] Antigens, CD30 / blood. Lymphoma, AIDS-Related / immunology. Lymphoma, B-Cell / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / physiopathology. Antigens, CD / blood. Biomarkers. CD4 Lymphocyte Count. HIV Infections / physiopathology. Humans. Interleukins / blood. Predictive Value of Tests. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16651853.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH H